Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


To identify an enzyme or isoenzyme

Subclass of:

435 - Chemistry: molecular biology and microbiology

435004000 - MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIP

435700100 - Involving antigen-antibody binding, specific binding protein assay or specific ligand-receptor binding assay

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20110201023MANNOSE 6-PHOSPHATE-BINDING ANTIBODIES AND THEIR USES - The present invention relates to an isolated antibody or antigen-binding fragment thereof which specifically binds to mannose 6-phosphate and methods for preparing such antibody or antigen-binding fragment thereof. The invention further relates to a nucleic acid molecule encoding such antibody or antibody fragment, an expression vector comprising such nucleic acid molecule and a host cell comprising such nucleic acid molecule or expression vector. The invention also relates to a method for purifying or concentrating a target molecule comprising at least one mannose 6-phosphate residue from a sample. In another aspect, the invention relates to a method for diagnosing a disease which is characterized by an absent or reduced modification of molecules with mannose 6-phosphate residues. Finally, the invention relates to the use of an antibody or antibody fragment of the invention for use in medicine, in particular for the diagnosis of a disease which is characterized by an absent or reduced modification of molecules with mannose 6-phosphate residues.08-18-2011
20090317830HEPATITIS C VIRUS NS2/3 ASSAY - The present invention provides an assay for the detection of the NS2/3 cleavage products NS2 or NS3 in the presence of uncleaved NS2/3. Following self-cleavage of NS2/3 to generate NS2 and NS3 cleavage products, a sample is incubated with a ligand specific for the recognition of NS2 or NS3 cleavage product in the presence of uncleaved NS2/3. There is provided a method for detecting a NS2/3 autocleavage product in a sample containing NS2/3 protease, whereby the amount of bound ligand detected correlates with the NS2/3 autocleavage activity. A further aspect of the present invention concerns ligands selectively recognizing one of the NS2 cleavage product or the NS3 cleavage product with minimal cross-reactivity with the uncleaved NS2/3 and the other cleaved product. The present invention provides antibodies that selectively recognize one of cleaved NS2 product or cleaved NS3 product with minimal cross-reactivity with the uncleaved NS2/3 and the other cleaved product.12-24-2009
20080261238Method for Differentiation of Factor XIII Deficiency States in Relation to Fibrinogen Deficiency States Using Thrombelastographic Techniques - The invention relates to a method for determining a factor XIII deficiency, a method for determining a fibrinogen deficiency, and a method for differentiating between a factor XIII deficiency and a fibrinogen deficiency by means of thrombelastographic techniques. On the basis of the evaluation of the thrombelastographic parameters, a rapid and a selective substitution of factor XIII and/or of fibrinogen in deficiency states is possible.10-23-2008
20090170126Prostasin Partial Peptide and Anti-Prostasin Antibody - An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.07-02-2009
20120183973BIOMARKER COMPOSITION FOR DETECTING DIABETIC RETINOPATHY AND DIAGNOSTIC KIT THEREFOR - Provided is a biomarker composition for detecting diabetic retinopathy, comprising at least one protein selected from the group consisting of proteins as set forth in SEQ ID NOS: 1 to 169, a method and a kit for diagnosing diabetic retinopathy using the same. The biomarker can provide fundamental information in researching vitreoretinal disorders, such as, diabetic retinopathy and the protein may be used in a method and a kit for diagnosing diabetic retinopathy with a molecule specifically binding thereto.07-19-2012
20100159477Reagents for the detection of protein phosphorylation in signaling pathways - The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, adhesion/extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding/repair/replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G/regulator proteins, inhibitor proteins, motor/contractile proteins, phosphatase, protease, Ser/Thr protein kinases, Protein kinase (Tyr)s, receptor/channel/cell suface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.06-24-2010
20080299585METHODS FOR DETECTION AND MEASUREMENT OF SECRETORY PHOSPHOLIPASE A2 LEVELS (sPLA2) IN BIOLOGICAL FLUIDS - Elevated levels of secretory phospholipase A12-04-2008
20090104627METHOD FOR DETERMINATION OF ENZYMATIC ACTIVITY - A novel modified polysaccharide, a solid phase to which the polysaccharide is adhered, methods for detecting N-deacetylase activity, N-sulfotransferase activity and N-deacetylase/N-sulfotransferase activity in a sample which utilizes said solid phase, and detection kits thereof.04-23-2009
20100151494FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS - The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.06-17-2010
20110195432METHODS FOR THE SELECTION OF THERAPEUTIC TREATMENTS FOR CANCER - Methods are disclosed for identifying subjects that would benefit from treatment with an inhibitor of HDAC6 deacetylase activity. The methods can include contacting a sample obtained from the subject with an of HDAC6 deacetylase activity detecting the amount of HDAC6 protein present in the tumor sample in comparison with a control. Such methods can be used to determine if a tumor in a subject is sensitive to treatment with an inhibitor of HDAC6 deacetylase activity. Also disclosed are methods for monitoring a response to a cancer treatment. Such methods are particularly useful in selecting a compound or multiple compounds for the treatment of cancer in a subject. Methods are also disclosed for identifying agents that inhibit cancer. The methods can include contacting at least one cell with a test agent and detecting an amount of HDAC6 protein in the cell in comparison to a control.08-11-2011
20100120065METHOD FOR DETERMINING ENDOGLYCOSIDASE (HEPARANASE) ENZYME ACTIVITY - The present invention provides a method for determining endoglycosidase activity, and in particular of the heparanase type, in a sample, and also a method for detecting compounds that modulate the activity of endoglycosidases and in particular endoglycosidases of the heparanase type.05-13-2010
20100120064ANTIBODY SPECIFIC TO INTACT HUMAN AUTOTAXIN, METHOD OF SCREENING THE SAME AND METHOD AND REAGENT FOR EXAMINING MALIGNANT LYMPHOMA BY ASSAYING AUTOTAXIN - A screening method is provided for antibody specifically recognizing naturally-occurring form of human autotaxin in a state in which it is present in the body without being denatured, comprising the steps of: binding a binding factor capable of capturing a candidate antibody of the antibody to a solid phase; binding the candidate antibody of the antibody to the binding factor; allowing naturally-occurring form of human autotaxin to react on a system in which the candidate antibody has reacted; and selecting an antibody that specifically recognizes the naturally-occurring form of human autotaxin by using as an indicator thereof the binding strength of the naturally-occurring form of human autotaxin to the antibody. Moreover, a detecting method for malignant lymphoma is provided comprising: measuring the concentration of autotaxin in a human specimen, and judging to be a malignant lymphoma in the case that value exhibits a significantly higher value than normal values comprised of measured values from normal healthy subjects.05-13-2010
20130078645BIOMARKERS - The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder. The biomarkers used are selected from cyclophilin A, cytosalic non-specific dipepditase, Caoctosin-like protein, Glucose-6-phosphate isomerase, uncharacterized protein KIAA0423, myosin 14, myosin 15, nicotinamide phosphoribosyltransferase, pyruvate kinase isozyme R/L, phosphoglyterate mutase 4.03-28-2013
20100075342Biomarker for ovarian cancer CTAP3-related proteins - The present invention provides a protein-based biomarker that is useful in qualifying ovarian cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarker can be detected by SELDI mass spectrometry.03-25-2010
20120244554METHOD FOR THE DIRECT MEASURE OF MOLECULAR INTERACTIONS BY DETECTION OF LIGHT REFLECTED FROM MULTILAYERED FUNCTIONALIZED DIELECTRICS - Method and apparatus for the quantitative determination of molecular interactions between ligands in solution and receptors immobilized on the surface of a solid transparent material coated by one or more antireflective dielectric layers, through direct measurement of the light reflected by the interface between the surface and the solution.09-27-2012
20130084582SEROLOGICAL MARKERS FOR DETECTING COLORECTAL CANCER AND THEIR APPLICATION FOR INHIBITING COLORECTAL CANCER CELLS - Embodiments relate to serological markers for detecting the colorectal cancer and applications of the serological markers. A phospholipid scramblase1 (PLSCR1), a stomatin-like protein 2 (STOML2) or a transport protein Sec61β (SEC61β) increases expression in the blood at the earlier stage of the colorectal cancer. Detecting the expression of the PLSCR1, STOML2 or SEC61β protein or an induced autoantibody of each protein in a blood sample is used to diagnose the colorectal cancer. Moreover, the serological marker improves the detection efficiency and the sensitivity in detecting the colorectal cancer and is used to predict the prognosis. The serological markers are applied in preparing a detection device or inhibiting the growth of the colorectal cancer cells.04-04-2013
20130034864Protein, An Antibody and Measurement of the Protein - Methods for determining the occurrence or level of a mammalian protein in a sample and methods for determining the capability of a compound to transform or to inhibit the transformation of a selected mammalian protein in pro-phospholipase B form to an enzyme active phospholipase B form employ a pro-phospholipase B (PLB-II) mammalian protein which comprises at least one SU2 subunit comprising SEQ ID NO: 3 and having a molecular weight within the range of 30-60 kDa. Methods for determining the capability of a compound to enhance or inhibit the enzymatic activity of a selected protein having phospholipase B enzyme activity employ a protein comprising an activated form of such a pro-phospholipase B (PLB-II) mammalian protein.02-07-2013
20130034863Apparatus and Methods for Detecting Inflammation Using Quantum Dots - Apparatus and methods for detecting an a biomarker indicative of an inflammatory condition, including a capillary tube adapted for one or more biomarkers to adhere to an interior surface thereof, a light source for energizing quantum dots conjugated with the biomarkers within the capillary tube, and a detection system for detecting and quantifying fluorescent energy emitted by the quantum dots in one or more predetermined wavelength ranges, each wavelength range being correlated to one and only one of the biomarkers. A method of stabilizing the fluorescence intensity of quantum dots is also disclosed.02-07-2013
20130040312DETECTION OF NGAL IN CHRONIC RENAL DISEASE - Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.02-14-2013
20130040311MONOCLONAL ANTIBODY AGAINST NECROSIS MARKER ERP29 AND USE THEREOF - [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth.02-14-2013
20130040310ULK1 COMPOSITIONS, INHIBITORS, SCREENING AND METHODS OF USE - This disclosure relates to methods and compositions useful for the treatment of cancer and diseases and disorders associated with autophagy.02-14-2013
20130040309Methods and Compositions for In-Vivo Enzyme Capture - The invention includes compositions, methods and kits for the in vivo identification of an enzyme that binds to a substrate. The invention comprises, in part, a photoreactive moiety to aid in identification of such an enzyme.02-14-2013
20090155814PROTEINS IN TYPE 2 DIABETES - The present invention relates to the use of naturally occurring compounds and derivatives thereof as markers for predisposition of diabetes related diseases. The invention also relates to a pharmaceutical composition for treatment of diabetes related diseases.06-18-2009
20100105076ANALYSIS KIT COMPRISING AT LEAST TWO MOLECULARLY IMPRINTED POLYMERS AND AT LEAST ONE MARKER, AND METHOD OF ANALYSIS USING SAME - The present invention relates to a kit for analysing at least one target molecule comprising at least a first molecularly imprinted polymer and a second molecularly imprinted polymer which are chemically identical or different, capable of interacting with the target molecule(s), and at least one marker, wherein said marker is either a competitive marker or marker capable of (i) of interacting with all or part of the recognition sites for the target molecule(s) of the second molecularly imprinted polymer and (ii) of being displaced from said recognition site(s) by the target molecule(s) when said molecularly imprinted polymer is placed in the presence of said target molecule(s), or an intrinsic marker or a constitutive unit of the second molecularly imprinted polymer, capable (i′) of interacting with all or part of the target molecule(s) when the latter interact(s) with all or part of its recognition sites for said target molecule(s) and (ii″) of consequently emitting a detectable signal.04-29-2010
20100041069METHODS FOR DIAGNOSING AND MONITORING LIVER DISEASES - A method of diagnosing a liver disorder in a subject is disclosed. The method comprises determining a level of sH2A and at least one additional liver marker in a sample of the subject wherein a change beyond a predetermined threshold in both the sH2A and the at least one additional marker with respect to a sample from a healthy individual is indicative of the liver disorder. Kits for diagnosing a liver disorder are also disclosed.02-18-2010
20100041068DEEPLY QUENCHED ENZYME SENSORS AND BINDING SENSORS - Sensors for detecting enzyme activity are provided that include a substrate module comprising a substrate for the enzyme of interest and a fluorescent label, a quencher, and a detection module. The detection module binds to the substrate module either before or after the enzyme acts on the substrate and sequesters the label from the quencher, resulting in an increased signal from the label. Sensors for detecting protein-protein interactions are also provided that include a quencher and a labeled first polypeptide. Binding of the first polypeptide to a second polypeptide sequesters the label from the quencher, resulting in an increased signal from the label. Methods using the sensors to detect enzyme activity and to screen for compounds affecting enzyme activity or to detect protein-protein interactions and to screen for compounds affecting protein-protein interactions, respectively, are also described.02-18-2010
20130029352METHODS FOR DIAGNOSING AND MONITORING THE PROGRESSION OF CANCER - Methods for measuring c-Met levels in urine and blood samples are provided. Methods for diagnosis and prognosis evaluation for cancer are also provided.01-31-2013
20130029353AUTOANTIBODY ENHANCED IMMUNOASSAYS AND KITS - The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte01-31-2013
20130029351A25 BACTERIOPHAGE LYSIN - The invention relates to the identification, sequencing, and isolation of an A25 bacteriophage lysin gene that expresses a protein involved in the lysis of bacterial cells during the phage life cycle. The invention further relates to methods for lysing certain bacteria using lysin, which are useful for example in a diagnostic procedure designed to detect these bacteria.01-31-2013
20090123941METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.05-14-2009
20130052659METHOD FOR MEASURING IgG-MEDIATED COMPLEMENT ACTIVATION - A method for measuring immunoglobulin G-mediated complement activation, includes the following steps: 02-28-2013
20100136577COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF PROLIFERATIVE ABNORMALITIES ASSOCIATED WITH OVEREXPRESSION OF HUMAN TRANSKETOLASE LIKE-1 GENE - Methods for in vitro diagnosis of carcinoma are disclosed. In one aspect the invention relates to methods such as detecting the level of transketolase like-1 polypeptide, which are especially useful for the detection of tumors and their precursory stages based on the detection of overexpression of human transketolase like-1 gene in biological samples. In another aspect the invention relates to methods for treatment of disorders associated with the overexpression of human transketolase like-1 gene. Methods for treatment may include gene therapeutic approaches as well as methods for inhibiting or reducing the activity of transketolase like-1 polypeptides.06-03-2010
20130089871MARKER FOR DETECTION AND/OR DISCRIMINATION OF NON-ALCOHOLIC STEATOHEPATITIS, METHOD FOR DETECTION AND/OR DISCRIMINATION OF NON-ALCOHOLIC STEATOHEPATITIS, AND KIT FOR USE IN THE METHOD - The detection of a non-alcoholic steatohepatitis patient and the accurate discrimination between a normal person and a non-alcoholic steatohepatitis patient can be achieved by measuring alanine-glyoxylate amino transferase in a sample.04-11-2013
20130071854METHODS FOR THE IDENTIFICATION AND CHARACTERIZATION OF HDAC INTERACTING COMPOUNDS - The present invention relates to methods for the identification and characterization (e.g. selectivity profiling) of HDAC interacting compounds using protein preparations derived from cells endogenously expressing HDACs or cell preparations containing said HDACs.03-21-2013
20130071855FLC AS BIOMARKER - The invention provides a method of identifying a subject likely to have liver disease, or for determining the prognosis of a subject previously identified as having a liver disease comprising detecting an amount of free light chains in a sample from the subject, wherein a higher amount of FLC is associated with an increased likelihood of the subject having a liver disease or an increased likelihood of having a poor prognosis of a liver disease. Assay kits for use in such methods are also provided.03-21-2013
20130059315Alpha-Amylase Mutants - The present invention relates to a method of constructing a variant of a parent Termamyl-like alpha-amylase, which variant has alpha-amylase activity and at least one altered property as compared to the parent alpha-amylase, comprises 03-07-2013
20130059314FRET-BASED METHOD FOR THE DETERMINATION OF PROTEIN PHOSPHATASE AND KINASE ACTIVITY - This disclosure relates to methods of determining activities of protein phosphatases and kinases. The disclosure further relates to methods of clinical monitoring of calcineurin activity and immunosuppression in patients and which may be used to predict transplant acceptance in patients.03-07-2013
20110059465SCREENING ASSAYS FOR AGENTS THAT ALTER INHIBITOR OF APOPTOSIS (IAP) PROTEIN REGULATION OF CASPASE ACTIVITY - The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP. In addition, the invention provides methods of modulating the ability of a population of cells to survive ex vivo by contacting the cells with an agent that alters the caspase inhibitory activity of an IAP in the cells.03-10-2011
20120309021DETECTION OF ANTIBODY THAT BINDS TO WATER SOLUBLE POLYMER-MODIFIED POLYPEPTIDES - The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.12-06-2012
20110014631METHOD FOR DIAGNOSING ACUTE CORONARY SYNDROME - This invention concerns a bioaffinity assay for quantitative determination in a sample of free PAPP-A, defined as the pregnancy associated plasma protein A (PAPP-A) that is not complexed to the proform of major basic protein (proMBP), wherein 01-20-2011
20090269784PROTEIN ENGINEERING OF MONOACYLGLYCEROL LIPASE (MGLL) - A number of soluble engineered forms of MGLL that are suitable for high-throughput screening and protein crystallization, as well as a crystallized form of monoacylglycerol lipase protein (MGLL) and descriptions of the X-ray diffraction patterns are disclosed. The engineered constructs of MGLL permit the expression and purification of protein suitable for crystallography or high-throughput screening and identification of ligands, which can function as active agents to MGLL. The X-ray diffraction patterns allow the three dimensional structure of MGLL to be determined at atomic resolution so that ligand binding sites on MGLL can be identified and the interactions of ligands with MGLL amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of MGLL.10-29-2009
20090075298METHOD OF ANALYZING ENZYME - A method of analyzing an enzyme, comprising (1) bringing a sample suspected of containing an enzyme to be analyzed into contact with an enzyme substrate which is immobilized on an insoluble carrier and can be cleaved by the enzyme, in a liquid, (2) separating the insoluble carrier from the liquid, and (3) analyzing a substrate or a fragment thereof which remains on the insoluble carrier and/or a fragment of the substrate which is released from the insoluble carrier into the liquid; and a kit for analyzing an enzyme, comprising at least an enzyme substrate which is immobilized on an insoluble carrier and can be cleaved by the enzyme, are disclosed.03-19-2009
20130065248REAGENTS AND METHODS FOR SIRTUIN CAPTURE - The invention provides a method of preparing a sirtuin complex. The invention also provides a method of detecting a sirtuin in a sample comprising use of the aforesaid sirtuin complex.03-14-2013
20130065246METHOD FOR DIAGNOSING MELANOCYTIC PROLIFERATIONS - The invention provides a method for diagnosing a melanocytic proliferation in a subject comprising staining a sample of lesional melanocytes with an antibody against soluble adenylyl cyclase (sAC) and interpreting the sAC staining pattern, which is associated with a diagnosis of a melanocytic proliferation. The sAC staining pattern, which is complex, is discriminatory and distinctive according to the nature of the melanocytic proliferation. The sAC staining pattern comprises one or more of dot-like Golgi staining, broad granular Golgi staining, diffuse cytoplasmic staining, nucleolar staining, incomplete granular nuclear staining, and pan-nuclear staining. The method of the invention is particularly useful in confirming or disaffirming a diagnosis reached through conventional histologic examination of a sample. Additionally, the invention provides a kit for use in interpreting melanocytic proliferations.03-14-2013
20130065247METHODS OF DIAGNOSING LATENT AND ACTIVE MALIGNANCIES - Disclosed are procedures and methods for diagnosing latent and active cancers in a subject. The described methods include the use of sandwich ELISA assays containing antibodies specific for certain epitopes on the A-protein. This enables the assay to discriminate between the monomelic and homopolymeric forms of A-protein.03-14-2013
20110020839METHODS AND COMPOSITIONS FOR DETECTING THE ACTIVATION STATE OF MULTIPLE PROTEINS IN SINGLE CELLS - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.01-27-2011
20090233316Protein, An Antibody and Measurement of the Protein - A novel mammalian protein related to human hypothetical protein FLJ22662 (SEQ ID NO: 1) and homologous hypothetical proteins from mammal species other than 09-17-2009
20090011432Detecting and Profiling Molecular Complexes - Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex.01-08-2009
20100086944Methods and Compositions for Diagnosis and Prognosis of Renal Artery Stenosis - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects in the context of renal artery stenosis (RAS). In particular, the invention relates to using assays that detect NGAL, their use to diagnose RAS in subjects suffering from hypertension, and their use in prognosis, particularly of mortality and worsening renal function.04-08-2010
20120237948COLLAGEN NEOEPITOPE ANTIBODY - The present invention provides a novel monoclonal antibody that is specific for a C-terminal neoepitope of a collagen fragment and has substantially equal binding affinity whether proline contained in the neoepitope is in a non-hydroxylated form or in a hydroxylated form, and an immunoassay, a measurement method, a kit and the like using the antibody. The antibody allows for quantification of a collagen fragment generated by digestion of a biological sample with a collagenase present in the sample, regardless of the presence or absence of a hydroxylated form of proline in the neoepitope.09-20-2012
20120237947Glutathione S-Transferase Omega 1 Wild Type Specific Antibody - The invention relates to a novel antibody which binds to wild type (wt) Glutathione S-transferase Omega 1 (wtGSTO1) but not to mutant (mut) GSTO1 and methods and uses based on the antibody. The antibody is based on novel haptens and immunogens.09-20-2012
20100028908NOVEL DETECTION SYSTEM - The present invention relates to methods of making nanoarrays for use in detecting species formed on the surface of the array using SE(R)RS. The methods can involve nanolithographic printing of a compound by dip pen nanolithographic printing. A SE(R)RS substrate can be used for the array and which can be selected from surfaces roughened by the oxidation-reduction cycle (ORC), island films, colloidal nanoparticles and surface-confined nanostructures. A coating or intermediate layer, such as a layer formed of nitrocellulose, can be provided between the compound and the SE(R)RS substrate. There are also provided arrays themselves and methods of using such arrays.02-04-2010
20110281280Methods and Compositions for Monitoring and Risk Prediction in Cardiorenal Syndrome - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.11-17-2011
20100261198METHODS OF DETECTION OF FACTOR XIA AND TISSUE FACTOR - The invention provides compositions and methods for the detection of Factor XIa or Tissue Factor (TF) activity in a sample using an antibody based clotting time prolongation assay. The invention provides methods for detection of FXIa or TF activity in a sample using a fluorogenic substrate. Further provided herein is a correlation between elevated levels of FXIa and/or TF with inflammation, acute coronary syndrome (ACS), myocardial infarction, coronary artery disease (CAD), heart failure, aortic stenosis, stroke, or transient ischemic attack. The frequency of FXIa and TF activity was substantially lower in individuals with stable coronary artery disease and no history of myocardial infarction. No FXIa or TF activity was observed in healthy individuals.10-14-2010
20120288872GENE DEFECTS AND MUTANT ALK KINASE IN HUMAN SOLID TUMORS - Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The invention also provides methods for determining the presence of these mutant polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.11-15-2012
20120288873BIOMARKERS FOR THE DETECTION AND SCREENING OF DOWN SYNDROME - The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.11-15-2012
20130022993COMPOUND, PHOSPHORYLATION INHIBITOR, INSULIN RESISTANCE IMPROVING AGENT, PREVENTIVE OR THERAPEUTIC AGENT FOR DIABETES, AND SCREENING METHOD - A new compound inhibiting phosphorylation of Ser727 of STAT3, a phosphorylation inhibitor containing the new compound, an insulin resistance improving agent and a preventive or therapeutic agent for diabetes; and a screening method for at least one of the insulin resistance improving agent and the preventive or therapeutic agent for diabetes.01-24-2013
20130022992IN VITRO ASSAY FOR QUANTIFYING CLOSTRIDIAL NEUROTOXIN ACTIVITY - Novel methods for determining the unknown biological activity of a clostridial neurotoxin in a sample with respect to the known biological activity of a clostridial neurotoxin in a reference sample, comprising the step of comparing the biological activity of a clostridial neurotoxin preparation with the biological activity of a standard preparation of a reference clostridial neurotoxin in certain in vitro systems.01-24-2013
20110281279CIRCULATING Epha2 RECEPTOR - Provided are compositions, methods, and kits relating to the detection of a circulating or soluble form of the EphA2 receptor tyrosine kinase.11-17-2011
20110300556MONOCLONAL ANTIBODIES DETECTION METHODS FOR ENZYMES THAT CONFER RESISTANCE TO 2,4-DICHLOROPHENOXYACETIC ACID IN PLANTS - Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of an aryloxyalkanoate dioxygenase enzyme.12-08-2011
20120009592ENPP1 (PC-1) GENE HAPLOTYPE ASSOCIATED WITH THE RISK OF OBESITY AND TYPE 2 DIABETES AND THEIR APPLICATIONS - The present invention is directed to a method for determining if a subject is at increased risk to develop obesity or pathology related to obesity by determining the presence of a haplotype comprising three specific SNPs in a DNA or RNA sample of this subject and/or an elevated serum ENPP1 protein concentration. The present invention also relates to a kit and to an isolated nucleic sequence, vector or recombinant cell comprises said ENPP1 gene haplotype. The invention further comprises a method for selecting a compound for the treatment or the prevention of obesity or pathology related to obesity and a method for determining the efficacy of a drug to reduce the risk of obesity or pathology related to obesity in a patient.01-12-2012
20110287449MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE - Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from healthy controls. Such comparison characterizes the test subject's risk of developing CVD.11-24-2011
20090162870FATTY ACID SYNTHASE IN LIVER DISEASE - Methods and compositions for detecting elevated fatty acid synthase (FAS) expression in the liver of a subject are disclosed. The detection may be of expression in liver cells per se or in a bodily fluid of a subject. Also disclosed are methods for identifying the presence or absence of liver disease or pathology in relation to elevated FAS. The disclosed methods may be practiced with various compositions comprising reagents for detecting FAS expression as described herein.06-25-2009
20110217719METHODS AND KITS FOR DIAGNOSING OBSTRUCTIVE SLEEP APNEA - The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject.09-08-2011
20090098577METHOD OF IDENTIFYING COMPOUNDS THAT MODULATE CASPASE 9 ACTIVITY VIA USE OF A KOSMOTROPIC SALT - The present invention discloses methods for activating Caspase 9 in such a way that it can be used in assays to discover modulators of Caspase 9.04-16-2009
20090098576Feline Pancreatic Lipase - Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples.04-16-2009
20090098575The Human E3alpha Ubiquitin Ligase Family - The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.04-16-2009
20100112598Novel Assay for Inositol Phosphorylceramide Synthase Activity - Disclosed is a simple and reproducible method for assaying inositol phosphorylceramide synthase activity that employs a fluorescence resonance energy transfer pair for measuring enzyme activity. The invention also includes a novel method for identifying IPC synthase inhibitors.05-06-2010
20090148866Antibodies and Improved Test Sample Handling Methods for Use in Assays for Myeloperoxidase - The present disclosure relates to isolated antibodies that can be used in an assay to determine the concentration levels of myeloperoxidase (MPO) in a test sample. Additionally, the present disclosure also relates to the use of improved test sample handling methods in assays in order to preserve the original MPO levels in the test sample.06-11-2009
20100267054Measuring The Activity Of Proteases - A method and apparatuses for determining the total content of proteases by means of measuring their enzyme activity after previous deinhibition is disclosed. In biological samples, lysosomal proteases are completely (e.g. in blood serum) or partly (e.g. in tissue homogenates) inhibited. A method proposed for the deinhibition entails immersing a solid support material (e.g. nylon or nitrocellulose) as plastic strip to which is linked, covalently or by adsorption, an inhibitor-binding substance which binds the inhibitor corresponding to the protease more strongly than the protease in the sample for measurement. After the deinhibition has taken place, the plastic strip is removed from the liquid sample for measurement, and the sample for measurement is passed on for measurement of the enzyme activity. Fluorogenic substrates from which the fluorogen 7-amino-4-trifluoromethylcoumarin is eliminated proved to be particularly advantageous for the activity measurement. These substrates make it possible for the sensitivity on measurement in microtitre plates with a fluorescence reader to be at least 10 times higher compared with conventional AMC substrates in blood serum, and thus for the fluorimetric determination of such enzyme activities in blood serum to be efficient with this measuring arrangement which is widely used in clinical laboratories.10-21-2010
20100120066METHOD FOR DETECTING INTERACTIONS BETWEEN TWO AND MORE BIOLOGICAL MACROMOLECULES - Methods for detecting interactions of biomolecules include (a) preparing a cell comprising (i) a first construct comprising a bait, a first labeling material and a translocation module; and (ii) a second construct comprising a prey and a second labeling material; (b) detecting the distribution of the first construct and the second construct in the cell. The methods are simplified and show significantly high accuracy.05-13-2010
20120034624OSCILLATING IMMUNOASSAY METHOD AND DEVICE - The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.02-09-2012
20090087864Procedure for the determination of the activity of the protease which activates factor VII from protein solutions - A procedure for the determination of the activity of the protease which activates blood clotting factor VII from protein solutions is describes, in which 04-02-2009
20120107833Antibody specific for a mammalian sphingosine kinase type 2 isoform protein and methods of use thereof - Polyclonal or monoclonal antibodies which are specific for a mammalian sphingosine kinase type 2 isoform protein and methods for detecting the presence of sphingosine kinase type 2 isoform using the antibodies.05-03-2012
20090203043Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways - The invention discloses 142 novel phosphorylation sites identified in insulin signaling pathways, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.08-13-2009
20090263829ALZHEIMER'S DISEASE BIOMARKERS AND METHODS OF USE - The invention encompasses biomarkers for AD, a method for detecting AD, a method of monitoring AD, and a kit for quantifying biomarkers for AD.10-22-2009
20090263830VISUALIZATION AND QUANTITIATION OF CELLULAR CYTOTOXICITY USING CELL-PERMEABLE FLUOROGENIC PROTEASE SUBSTRATES AND CASPASE ACTIVITY INDICATOR MARKERS - This invention provides a non-radioactive assay to monitor and quantify the target-cell killing activities mediated by cytotoxic T lymphocytes (CTLs). This assay is predicated on the discovery that apoptosis pathway activation and, in particular, caspase activity, provides a measure of cytotoxic effector cell activity. In one embodiment, measurement of CTL-induced caspase activation in target cells is achieved through detection of the specific cleavage of fluorogenic caspase substrates. This assay reliably detects antigen-specific CTL killing of target cells, and provides a more sensitive, more informative and safer alternative to the standard 10-22-2009
20100099118METHODS OF DETERMINING TOTAL PON1 LEVEL - A method of determining an amount of total PON1 in a sample of a subject is disclosed. The method comprises: 04-22-2010
20100099119Detecting a Bacterial Process in Chronic Rhinosinusitis - The present invention provides a method for identifying bacterial induced rhinosinusitis. The method comprises obtaining a nasal or paranasal mucus sample and detecting the presence of neutrophil degranulation in the mucus sample. Degranulation of neutrophils can be determined by morphological analysis of the cells in the mucus or by detection of released (i.e., “free”) granule content markers such as neutrophil elastase or myeloperoxidase. Based on an accurate determination of the cause of sinusitis as described herein, an appropriate treatment can be instituted.04-22-2010
20110201022ASSAYS FOR DETECTION OF PHENYLALANINE AMMONIA-LYASE AND ANTIBODIES TO PHENYLALANINE AMMONIA-LYASE - Provided herein are methods of detecting the presence of a pegylated enzyme, an enzyme-specific antibody (e.g., a neutralizing antibody or of a particular isotype), or a polyethylene glycol (PEG)-specific antibody in a sample, such as a bodily fluid or tissue of a patient. In certain embodiments, the enzyme is phenylalanine ammonia-lyase (PAL), such as 08-18-2011
20110201021USE OF THE IRAP PROTEIN FOR IMPLEMENTING METHODS OF DIAGNOSIS AND OF PROGNOSIS - The use of the IRAP protein for implementing methods of diagnosis and of prognosis.08-18-2011
20080274476Assay Method - There is disclosed a method for determining the activity of gamma-secretase in a text subject, using a biological sample from the subject.11-06-2008
20090286260MYELOPEROXIDASE DETECTION IN DIAGNOSIS AND PROGNOSIS OF HEMATOPOIETIC DISORDERS - The present invention relates to the diagnosis of hematopoietic disorders and to determining the prognosis of patients affected by such disorders. The methods generally comprise determining a level of myeloperoxidase in a body fluid sample from the individual and using the level as a factor for diagnosing the disorder in the mammal or as a factor for determining the prognosis of a patient diagnosed with such a disorder. Myelodysplastic syndrome, acute myeloid leukemia and chronic myeloid leukemia are exemplary disorders. Also provided are method of cancer therapy involving reducing the level of myeloperoxidase in the body fluid of the individual.11-19-2009
20090104628Method for quantifying phosphokinase activity on proteins - The invention involves a method for measuring phosphorylation of proteins at specific sites and, as such, is an indicator of the protein kinase activity of enzymes capable of phosphorylating those sites. The method involves the in vitro or in vivo phosphorylation of a target protein at a specific serine, threonine or tyrosine residue, subjecting that protein (non-phosphorylated) to reaction mixture containing all reagents, including phosphokinase which allow the creation of a phosphorylated form of protein. The phosphorylated protein is measured by contacting it with an antibody specific for the phosphorylation site(s). The invention includes antibodies useful in practicing the methods of the invention. The invention particularly relates to all proteins modified by phosphorylation and dephosphorylation as illustrated by Tau, Rb and EGFR proteins and antibodies specific for the site of phosphorylation of the Tau, Rb or EGFR proteins.04-23-2009
20100221749THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF - The invention relates to a three-functional pseudo-peptidic reagent, to the various uses thereof, in particular for preparing bioluminescent reagents or optionally luminescent bio-conjugates, to the use of said reagents and bio-conjugates for functionalising solid substrates, and to the use of solid substrates thus functionalised in the detection of molecules of interest.09-02-2010
20120295280CITRULLINATED PEPTIDES FOR DIAGNOSING AND PROGNOSING RHEUMATOID ARTHRITIS - The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided.11-22-2012
20120295281SPECIFIC SALIVARY BIOMARKERS FOR RISK DETECTION, EARLY DIAGNOSIS, PROGNOSIS AND MONITORING OF ALZHEIMER'S AND PARKINSON'S DISEASES - Methods by which specific biomarkers in saliva are used for risk detection, early diagnosis, prognosis and monitoring of Alzheimer's and Parkinson's diseases.11-22-2012
20080274478NOVEL AROMATIC PRENYLTRANSFERASES, NUCLEIC ACIDS ENCODING SAME AND USES THEREFOR - In accordance with the present invention, a novel aromatic prenyltransferase, Orf2 from 11-06-2008
20090170125Cellular assay method for identifying pkc-0 inhibitors - The invention relates to a method for investigating the modulating effect of a test substance on a PKCθ-dependent signal transduction pathway or for finding a PKCθ modulator in a human or animal cell, including the steps 07-02-2009
20080274477Forms of Factor Xiia - A 53 Kd novel form of factor XIIa and related products, including nucleic acid molecules, monoclonal and polyclonal antibodies and hybridoma cell lines. Also assays for a 53 Kd form of factor XIIa and uses of said assays in diagnostic and prognostic methods, for example in the prediction of survival following myocardial infarction.11-06-2008
20080311591Differential Immunoassay - The invention provides assay methods and kits that in general measure the level of a first analyte in a sample reduced by the level of a second analyte present in the same sample. In one embodiment, where levels of a first analyte from a first source is desirably determined and first analyte in the sample released from a second source is accompanied by proportional co-release of a second analyte, the assay identifies the level of first analyte released only from the first source. For analytes within bodily fluids, the assay can differentiate between elevated levels of analyte specific to the particular physiological or pathological state and elevated levels not specific to the particular state, providing single tests with diagnostic utility.12-18-2008
20120295282METHODS OF DIAGNOSING OR TREATING PROSTATE CANCER USING THE ERG GENE, ALONE OR IN COMBINATION WITH OTHER OVER OR UNDER EXPRESSED GENES IN PROSTATE CANCER - The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.11-22-2012
20080206787Process to determine enzyme activity - The present invention provides for various processes for determining enzyme activity. In one embodiment, a process for detecting an enzyme activity includes contacting a blood component with a substrate comprising a cleavage site of the enzyme and a tag moiety to produce a sample comprising a cleavage product having a known mass, and placing the sample in contact with a SELDI sample chip which has surface moieties which bind to the cleavage product. In another embodiment, the process further includes subjecting the SELDI sample chip to SELDI mass spectrometry to identify the cleavage product. The present invention also provides for a kit which includes a SELDI sample chip having surface moieties capable of binding to an enzyme cleavage product.08-28-2008
20080227115Inhibition of cancer metastasis - The present invention relates to compositions and methods for cancer diagnosis, treatment and drug screening. In particular, the present invention provides compositions and methods for targeting the nuclear translocation of IkB kinase-α (IKKα) and the IKKα-mediated suppression of Maspin expression observed in metastatic prostate cancer cells.09-18-2008
20100143940(3R)-HYDROXYACYL-ACP DEHYDRATASE ENZYMES USED IN THE BIOSYNTHESIS OF MYCOLIC ACIDS AND USE OF SAME FOR SCREENING ANTIBIOTICS - The invention relates to (3R)-hydroxyacyl-ACP dehydratase enzymes involved in the biosynthesis of mycolic acids, and to the use of same for screening antibiotics, medicaments that can be used to treat infections in humans or in animals, caused by 06-10-2010
20090136969Lipoprotein Associated Phospholipase A2, Inhibitors Thereof and Use of the Same in Diagnosis and Therapy - The enzyme Lp-PLA05-28-2009
20090186367DIAGNOSIS OF FERTILITY CONDITIONS USING A SERINE PROTEASE - The present invention relates to a method of diagnosing an infertility condition in a human female subject, the method comprising detecting pregnancy-related serine protease (PRSP) protein in a test sample taken from said subject at between 7 and 20 weeks into pregnancy; detecting PRSP protein in a test sample from a fertile control mammal taken within the same period; and comparing the PRSP protein in the test sample with the PRSP protein detected in the control sample, wherein a change in PRSP protein in the sample compared to the control sample is indicative of an infertility condition.07-23-2009
20130217033BIOMARKER FOR MONITORING DEVELOPMENT OF DISEASES AND ASSESSING THE EFFICACY OF THERAPIES - The invention concerns a method for monitoring the development of a disease in a patient, and for assessing the efficacy of a therapy influencing on the CD73 level or activity in the patient, in particular a cytokine therapy or a statin therapy. CD73 in a tissue fluid drawn from the patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid.08-22-2013
20090081704COMPOSITIONS, METHODS AND KITS FOR REAL-TIME ENZYME ASSAYS USING CHARGED MOLECULES - Compositions, methods and kits useful for, among other things, detecting, quantifying and/or characterizing enzymes.03-26-2009
20110229911AZUROPHILIC GRANULE PROTEASES AS MARKERS IN CARDIOLOGICAL DISEASES - The present invention is concerned with an assay for detecting and/or determining the level of a protease from azurophilic granules of polymorphonuclear neutrophils or a complex thereof with an endogenous inhibitor for risk stratification and/or prognosis and/or therapy control and/or monitoring of a patient having a cardiological disease or condition.09-22-2011
20110223616HuR-Associated Biomarkers - The present invention relates to methods of identifying gene targets, including methods of using ribonucleoprotein (RNP) immunoprecipitation-microarrays to identify cancer gene targets, such as subsets of RNP-associated mRNAs in breast cancer cell lines. Also presented, are ribonucleotide binding protein-associated biomarkers, panels or sets of ribonucleotide binding protein-associated biomarkers, methods and compositions comprising ribonucleotide-binding protein, associated nucleotides, nucleotide arrays, and kits to facilitate the diagnosis of and monitoring the disease status or progression of treatment of breast cancers, including drug-resistant breast cancers.09-15-2011
20090081703METHOD FOR DETECTING DEEP VENOUS THROMBOSIS - A method for detecting deep vein thrombosis (DVT) in humans includes the steps of assaying a collected blood sample and measuring the amount of Lp-PLA03-26-2009
20090053735Vector expressing n-deacetylase/n-sulfotransferase 2 - An object of the present invention is to provide an expression vector that allows for stable production of N-deacetylase/N-sulfotransferase 2 in large amounts and a process for production of N-deacetylase/N-sulfotransferase 2 using the same. The present invention provides a recombinant baculovirus expression vector obtained by incorporating into baculovirus DNA, a DNA fragment having lobster L21 DNA, DNA encoding gp67 signal peptide and DNA encoding the 79th to 883rd amino acids of human N-deacetylase/N-sulfotransferase 2 in this order in the 5′ to 3′ direction.02-26-2009
20090053738PROTEASE DETECTION - A method of detecting a protease in a sample. The method comprises providing an analyte degradable by the protease. The analyte is contacted with the sample. The degradation products of the analyte or the residual undegraded analyte is detected in a binding assay.02-26-2009
20090220990METHOD AND KIT FOR DETECTING CONDITION IN PATIENT WITH DISTURBANCE OF CONSCIOUSNESS - A method for detecting a condition in a patient with disturbance of consciousness, by analyzing an amount and/or activity of a von Willebrand factor-cleaving protease, and a kit for detecting a condition in a patient with disturbance of consciousness, comprising an antibody or a fragment thereof which specifically binds to a von Willebrand factor-cleaving protease, or a von Willebrand factor or a fragment thereof, are disclosed. Examples of the detection of a condition include a detection of cerebrovascular disease, a detection of arteriosclerotic vascular disease, and a detection or prediction of severity.09-03-2009
20080261240METHOD - A method for attenuating a microorganism which comprises inhibiting in the microorganism a metabolic pathway essential for viability, by promoting use of the substrate of the pathway in a different metabolic pathway which is non-essential to the microorganism whereby the substrate is unavailable to the essential pathway and the micro organism is attenuated.10-23-2008
20080261239DETECTING MOLECULAR INTERACTIONS - The present disclosure features a variety of compositions, kits, and methods that are useful for, inter alia, detecting and/or analyzing an interaction between two molecules, a target molecule and a target-specific binding agent which can be, e.g., proteins, nucleic acids, saccharides or polysaccharides, small molecules, or combinations of any of the foregoing. The compositions, kits, and methods can also be used, e.g., to detect the presence or absence of an enzymatic activity (e.g., a kinase activity, a protease activity, or a phosphatase activity) in a sample; to identify a compound that modulates an interaction between two molecules; or to identify compounds that modulate the activity of an enzyme.10-23-2008
20090117591Fibrosis Markers - The invention relates to the use of a combination of at least two markers that are selected from among Uromodulin, MAC2BP, AGP1 and Cathepsin A, for the in vitro detection of fibrotic alterations. In addition, the invention relates to a kit for determining the levels of said markers in a biological sample.05-07-2009
20090239242Method for the early identification and prediction of kidney injury - A method for the early identification and prediction of elevated blood creatinine levels resulting from a reduction in kidney function in a subject, comprises contacting a urine sample from the subject with a capture molecule for a biomarker specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of elevated blood creatinine levels resulting from a reduction in kidney function. The method can be used to detect Acute Kidney Injury (AKI) caused by many conditions or diseases or through the administration of drugs. The method can indicate and/or predict a reduction in kidney function significantly earlier than the current standard creatinine test. Methods for predicting a need for renal replacement therapy (RRT) are also disclosed.09-24-2009
20090258375ASSAYS FOR DETECTING PREGNANCY-ASSOCIATED GLYCOPROTEINS - Disclosed are methods and compositions for detecting pregnancy in an animal by means of assaying peptidase activity of one or more Pregnancy Associated Glycoproteins (PAGs). In certain aspects, methods also comprising use of an antibody that binds immunologically to a PAG that displays proteolytic activity are provided. Substrates of proteolytic PAGs are also provided, as are kits, and methods of use. Further, methods of purifying PAGs based on their proteolytic activity are also provided.10-15-2009
20090258374Multisignal Labeling Reagents, and Processes and Uses Therefor - The present invention provides multisignal labeling reagents and these are useful in a number of biochemical applications, including the manufacture of biomolecular probes and their use in detecting or amplifying analyte-specific moieties.10-15-2009
20090142777Reagents for the detection of protein phosphorylation in leukemia signaling pathways - The invention discloses 424 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Cytoskeletal proteins, Cellular Metabolism enzymes, G Protein/GTPase Activating/Guanine Nucleotide Exchange Factor proteins, Immunoglobulin Superfamily proteins, Inhibitor proteins, Lipid Kinases, Nuclear DNA Repair/RNA Binding/Transcription proteins, Serine/Threonine Protein Kinases, Tyrosine Kinases, Protein Phosphatases, and Translation/Transporter proteins.06-04-2009
20110143369METHOD FOR DETERMINING TREATMENT OF DISSEMINATED INTRAVASCULAR COAGULATION - A method for determining an appropriate treatment option for a patient who has been diagnosed with disseminated intravascular coagulation (DIC) but who may have thrombotic thrombocytopenic purpura (TTP), by analyzing the amount and/or enzyme activity of a von Willebrand factor (vWF)-cleaving protease (ADAMTS13) and the amount of vWF in a patient that has been diagnosed with DIC is disclosed. Using the method of the present invention, a differential diagnosis of patients with thrombotic thrombocytopenic purpura (TTP) can be made from among patients diagnosed with DIC, which could not previously be distinguished on the basis of only clinical findings or known markers. Also disclosed is a kit for determining an appropriate treatment option, the kit comprising an antibody or a fragment thereof which specifically binds to ADAMTS13.06-16-2011
20120196299METHOD FOR DETECTION OF INTESTINAL, AND BLOOD-BRAIN BARRIER PERMEABILITY AND TESTING MATERIALS THERETO - Methods, assays, and apparatus are disclosed for testing of antigens associated with intestinal and/or blood-brain barrier permeability. For example, blood, saliva or other bodily fluid can be tested for binding (1) to a bacterial toxin (preferably a lipopolysaccharide), and (2) binding to tissue antigens selected from at least one of (a) a gut-related antigen and (b) a blood brain barrier-related antigen. Analysis of test results can be used to assist in detecting and diagnosing diseases associated with leaky gut syndrome (whether due to paracellular or transcellular pathways, and whether due to bacterial toxins or some other cause) and/or to diseases associated with excessive blood brain barrier permeability, which are contemplated herein to include both neuroinflammation and/or neuroautoimmunity conditions, and especially amyotrophic lateral sclerosis, Parkinsons disease, multiple sclerosis, Alzheimer's, or peripheral neuropathy, and major depression.08-02-2012
20130122518WELLNESS PANEL - A panel for monitoring levels of biomarkers, including an assay having at least one inflammation monitoring test, at least one oxidative stress monitoring test, and at least one antioxidant activity monitoring test. A method of monitoring an individual's health, by collecting a sample from the individual, applying the sample to an assay panel, performing at least one inflammation monitoring test, at least one oxidative stress monitoring test, and at least one antioxidant activity monitoring test in the panel, and determining levels of biomarkers related to inflammation, oxidative stress, and antioxidant activity and therefore providing information regarding the individual's relative health and/or risk of developing one or more diseases.05-16-2013
20090053736Homogeneous Chemiluminescent Immunoassay for Analysis of Iron Metalloproteins - The present invention relates to assays and kits for detecting or quantifying iron metalloprotein in test samples.02-26-2009
20090117592Altered Intracellular Localization of BRK/Sik Protein Tyrosine Kinase in Human Prostate Tumors - The invention provides methods for detecting abnormal prostate conditions, such as benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), and adenocarcinoma, in an animal by comparing the amount of the Breast Tumor Kinase (BRK) tyrosine kinase in the nuclei of prostate luminal epithelial cells in a test sample with an amount of nuclear BRK protein in epithelial cells of normal prostate glands.05-07-2009
20100184089DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL - A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.07-22-2010
20120244553BIOMARKER OF ALLERGIC DISEASE AND USE OF THE SAME - A biomarker is provided for an allergic disease caused by an allergic reaction that is caused not exclusively by histamine release, such as pruritus, and use of the same. Use of Granzyme A as a biomarker makes it possible to provide an indication for chronic itching skin disease, for which existing antiallergic drugs have little effect, and easily and adequately allow diagnosis of the disease. It is possible to, for example, make a diagnosis of an allergic disease with an IV type allergy-like reaction not depending on the antigen-antibody reaction system. Screening with the use of Granzyme A enables the development of novel remedies for allergic diseases. Moreover, a drug capable of specifically controlling the action of a granzyme enables treatment of allergic disease with little side effect.09-27-2012
20100216161Method for identifying protease inhibitors - The invention describes a method for assaying HCV NS3 protease activity using an NS3•4A protease molecule. The invention also provides a method for screening and identifying modulators of NS3 protease.08-26-2010
20100240067APPARATUS AND METHOD FOR ASSAYING COAGULATION IN FLUID SAMPLES - This invention is a disposable cartridge for use at the patient side to perform traditional coagulation assays on fresh whole blood or blood derivative samples. The cartridge, in use with an electronic analyzer allows a fluid sample to be metered and quantitatively mixed with reagents which activate the coagulation cascade. An artificial substrate for thrombin, the enzyme whose action results in clot formation is also provided. Clot formation is subsequently detected using a microfabricated sensor also housed within the cartridge which detects electrochemically the product of the thrombin reaction upon the synthetic substrate.09-23-2010
20130217034PROCESS FOR AVOIDING FALSE POSITIVE RESULTS IN A DETECTING PROCESS OF AN INFLAMMATION INDICATOR IN A RINSE SOLUTION FOR TAKING UP GINGIVAL CREVICULAR FLUID - A process for avoiding false positive results in a detecting process of an inflammation indicator from the matrix metalloproteinase (MMP) family in a gingival crevicular fluid (GCF), wherein said GCF, which is obtained from a mouthrinse or saliva, is filtered before said inflammation indicator from the MMP family is assayed.08-22-2013
20130217035BIOLOGICAL MOLECULE DETECTING APPARATUS AND BIOLOGICAL MOLECULE DETECTING METHOD - A configuration was adopted, in which the orientations of free molecules and binding molecules within a solution are switched by switching the vibration direction of orientation controlling light, thereby switching the amount of light emitted by each free molecule and each binding molecule. There is a difference in the amounts of time required for the orientations of the free molecules and the binding molecules to switch accompanying the switch in the emission direction of the orientation controlling light. Therefore, the timings at which the amounts of light emitted by each type of molecule increase differ. Accordingly, the fluorescence contributed by fluorescent molecules associated with free molecules and the fluorescent molecules associated with binding molecules can be respectively calculated, even if all of the fluorescent molecules within the solution emit fluorescence. Thereby, the concentration of a detection target substance can be accurately measured with a simple structure.08-22-2013
20100209941METHOD, DEVICE AND KIT FOR DETERMINING CONDITIONS RELATED TO A DYSFUNCTION OF THE RENAL PROXIMAL TUBULE - A method, device and kit are disclosed for determining a condition related to dysfunction of the Renal Proximal Tubule (RPT) by detecting the presence of type III Carbonic Anhydrase, CAIII, in a urine sample of a subject. The method is used for diagnosis and to monitor the progress of a condition, and to determine the efficacy of a treatment.08-19-2010
20080293078Method For the Detection of Atp in a Sample With the Aid of Luminescene and a Computer Programme For That Purpose - The present invention relates to a method for detecting ATP in a sample by using luminescence, wherein a luminescence reagent is added to the sample that has not undergone any pre-treatment with an extractant in order to effect the formation of an ATP complex, wherein the luminescence of the ATP com lex thus formed is measured.11-27-2008
20100136576In Vitro Method for Diagnosing Prostate Cancer - The invention relates to an in vitro method for diagnosing prostate cancer and to antibodies and fragments thereof directed against CK2-α and their use for the diagnosis and prognosis of prostate cancer.06-03-2010
20090075299Diagnostic Methods - The present invention relates to methods of diagnosing cancerous conditions in a patient, as well as methods of monitoring the progression of a cancerous condition and/or methods of monitoring a treatment protocol of a therapeutic agent or a chemotherapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.03-19-2009
20090311719IN VITRO METHOD FOR DIAGNOSING NEURODEGENERATIVE DISEASES - Disclosed is an in vitro method for the detection, for the determination of the severity and for the assessment of the progress and prediction of neurodegenerative diseases, in which the presence and/or concentration of carbamoyl phosphate synthetase 1 (CPS 1) is determined in a biological fluid of a patient who suffers from a neurodegenerative disease or is suspected of suffering from such a disease, and conclusions about the presence, progression, severity or success of a treatment of the neurodegenerative disease are drawn on the basis of the determined presence and/or concentration of CPS 1 or the non-detectability of a CPS 1 immune reactivity.12-17-2009
20090111124Kinase peptides and antibodies - The invention relates to novel kinase peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of a kinase-mediated disease, as well as for determining or monitoring the efficacy of treatment.04-30-2009
20100297667METHOD FOR DIAGNOSIS OF DISEASE USING QUANTITATIVE MONITORING OF PROTEIN TYROSINE PHOSPHATASE - The present invention relates to a method for quantifying protein tyrosine phosphatase (referred as PTP hereinafter) in biosamples, precisely a diagnostic method for disease by quantifying PTP using mass spectrometry and profiling of comparative PTP levels. By quantifying PTP in biosamples and profiling thereof according to the method of the present invention, disease can be diagnosed and diverse disease conditions and health conditions can be confirmed via profiling.11-25-2010
20100297666METHODS FOR DETERMINATION OF PROTEIN PHOSPHATASE ACTIVITY, AND USES IN PREDICTING THERAPEUTIC OUTCOMES - One aspect of the present disclosure encompasses methods for determining a protein kinase or phosphatase activity in a biological sample, comprising: contacting in a reaction mix a first test sample and a fluorescently-labeled peptide substrate capable of being modified by a protein phosphatase or a protein kinase, contacting the reaction mix with a TiO11-25-2010
20130130275IMMUNOASSAY METHODS AND REAGENTS FOR DECREASING NONSPECIFIC BINDING - Methods and kits for reducing non-specific binding in an immunoassay for PIVKA-II in a test sample are described, in which the test sample is reacted with an anti-prothrombin antibody in the presence of one or more of the following additives: skim milk, saponin, CaCl05-23-2013
20130130276METHOD FOR DETECTING GASTRIC CANCER - The object of the present invention is to provide a method for detecting gastric cancer, and a kit for detecting gastric cancer. The object can be solved by a method for detecting gastric cancer characterized by analyzing β1,4-N-acetylgalactosamine transferase 1. According to the present invention, gastric cancer patients can be detected at high rates, even early stage gastric cancer patients without a subjective symptom.05-23-2013
20100297665METHOD FOR TESTING AND SCREENING P38 MAP KINASE MODIFIERS - This invention provides methods for treating diseases associated with elevated p38 mitogen-activated protein kinase activity. Moreover, the invention provides methods for testing a candidate compound for a p38 mitogen-activated protein kinase modifying activity by calculating the level of relocalization of an SMN complex component from the cytoplasm to the nucleus of a cell. Additionally, the invention provides a kit and a system for calculating the same.11-25-2010
20100248263BIOMARKERS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION - The invention relates to proteins associated with age-related macular degeneration (AMD). These proteins, which are present in blood, are expressed in individuals with AMD at either elevated or reduced levels compared to healthy individuals. The invention provides methods for diagnosing AMD. The invention provides methods for assessing the efficacy of treatment of AMD. The invention provides methods for monitoring the progression of AMD.09-30-2010
20100304405COMBINATORIAL DISCOVERY OF ENZYMES WITH UTILITY IN BIOMASS TRANSFORMATION - Methods for the cell-free identification of polypeptide and polypeptide combinations with utility in biomass transformation, as well as specific novel polypeptides and cell-free systems containing polypeptide combinations discovered by such methods are disclosed.12-02-2010
20090081702DISCRIMINATON OF CARDIAC DYSFUNCTION IN PREGNANT FEMALES - The present invention relates to a method for diagnosing if a pregnant woman suffers from a cardiac dysfunction, comprising the steps of a) measuring the level of a natriuretic peptide in a sample b) measuring the level of placental growth factor and/or sFlt-1 or a variant thereof in a sample, wherein an increased level of a natriuretic peptide and a decreased level of placental growth factor and/or an increased level of sFlt-1 or a variant thereof indicates the presence of a placenta-associated cardiac dysfunction, and wherein an increased level of a natriuretic peptide and a not decreased level of placental growth factor and/or a not increased level of sFlt-1 or a variant thereof indicates the presence of a cardiac dysfunction related to heart disease. The present invention also relates to an array, to an immunological rapid test, to the use of corresponding kits, and to methods for a decision support for the possible treatment of a pregnant woman suffering from a cardiac dysfunction.03-26-2009
20100167310Reagent for Measuring Agglutination and Method of Measuring Agglutination - [PROBLEMS] To provide a reagent for measuring agglutination by using a reaction accelerator, which causes no spontaneous agglutination of receptor-sensitized carrier particles in the coexistence of these carrier particles, and a measurement method.07-01-2010
20110045494CANCER DETECTION METHODS AND TECHNIQUES - A method is provided for detecting and/or measuring the occurrence of an enzyme in the form of CYP1B1 in a patient for the detection of cancer in said patient. The method includes the steps of administering a reporter substrate to a patient; taking a bodily fluid and/or tissue sample from the patient after one or more pre-determined periods of time; and analyzing the bodily fluid and/or tissue sample in vitro for the occurrence and/or measurement of a metabolite of the reporter substrate caused as a result of metabolism of the reporter substrate by said enzyme in said patient during said pre-determined period of time.02-24-2011
20100136579BIOMARKERS USEFUL IN LIVER FIBROSIS DIAGNOSIS - Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and β-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis.06-03-2010
20090325193Diagnostic Test For The Detection Of A Molecule Or Drug In Whole Blood - The invention provides methods of preparing a test sample for use in an assay for detecting an analyte bound by an intracellular ligand. The methods typically involve contacting the test sample with an assay reagent comprising: a lysis reagent; and a protease that has proteolytic activity for said intracellular ligand; to form a mixture compatible for use in an immunoassay without subsequent extraction steps. Other aspects of the invention include related immunoassays and test kits.12-31-2009
20090035789MONITORING ENZYME MIXTURES - This invention provides a method for simultaneously detecting the presence of at least two enzymes in a sample, said method comprising the steps of; i) providing a first substrate for a first enzyme, said first substrate being labeled with a first fluorophore, ii) providing a second substrate for a second enzyme, said second substrate being labeled with a second fluorophore, iii) exposing the labeled substrates to the sample to allow the first and second enzymes present in the sample to interact with respective first and second fluorophore-labeled substrates to form respective first and second fluorophore-labeled substrate fragments; and, detecting the presence of said fluorophore-labeled substrate fragments.02-05-2009
20090162871Mutants of the factor VII-activating protease and detection methods using specific antibodies - Mutants of the DNA sequence coding for the protease (FSAP) which activates blood clotting factor VII and single-chain plasminogen activators, the mutants comprising a G/C base exchange at nucleotide position 1177 and/or a G/A base exchange at nucleotide position 1601, are described. The corresponding protease has a Glu/Gln exchange at amino acid position 393 and/or a Gly/Glu exchange at amino acid position 534. Diagnostic methods which are used for detecting FSAP in body fluids or tissue cells and also for identifying patients with genetic heterozygous or homozygous FSAP expression are also described. In addition, antibodies against FSAP and its mutants are disclosed and diagnostic methods which can be used to detect antibodies against FSAP and its mutants are specified.06-25-2009
20110097737Methods and Compositions for Targeting Proteins of Interest to the Host Cell Envelope - Methods and compositions are provided for producing membrane proteins or toxic proteins from recombinant DNA introduced into a prokaryotic host cell by targeting the expressed proteins to the envelope of the host cell. The methods and compositions utilize a protein vehicle fused to a protein of interest. The fusion protein may contain one or more protease cleavage sites to separate the protein of interest from the protein vehicle either in vivo or in vitro. The protein vehicle is characterized by a membrane-tar peptide and a trans-membrane segment separated by a cytoplasmic amino acid sequence that includes a cytoplasmic affinity-binding domain.04-28-2011
20110097736METHODS OF DETERMINING LEVELS OF FREE AMINO ACID AND DIPEPTIDES AND DIAGNOSING ALZHEIMER'S DISEASES - Provided herein are methods of diagnosing Alzheimer's disease (“AD”) based on characteristic changes of the levels of certain free amino acids or dipeptides (collectively termed as “AD diagnosis markers”) in the body fluid sample of an individual, carnosine synthesis activities in the plasma, and dopamine synthesis activities in the plasma. Also provided are methods of simultaneously determining the levels of at least two free amino acids or dipeptides in the biological fluid sample of an individual.04-28-2011
20110097738PLASMA BIOMARKER TOOL FOR THE DIAGNOSIS OF LIVER CANCER COMPRISING LIVER CARBOXYLESTERASE 1 AND LIVER CANCER SCREENING METHOD - The present invention relates to a plasma biomarker for diagnosing hepatocellular carcinoma (HCC), in particular to the discovery of a protein in plasma using 2-D fluorescence differential gel electrophoresis (2-D DIGE), immunoprecipitation and Nano-liquid chromatography mass spectrometry (Nano-LC-MS/MS) system that was unknown on the basis of conventional techniques. By demonstrating the presence of liver carboxylesterase 1 (hCE1) in human plasma and confirming that its secretion level is higher in patients with HCC than in healthy volunteers, this invention may be used as a screening method to diagnose HCC at an early stage.04-28-2011
20090215080METHODS FOR IDENTIFICATION OF INHIBITORS OF ENZYME ACTIVITY - The invention discloses compositions and methods of synthesis to create novel ligands and drugs and identifying such compounds as inhibitors of enzyme targets for use in the treatment of clinical disorders, including cancer, infectious diseases, parasitic infestations, neurological disorders, reproductive disorders, inflammatory disorders, circulatory disorders, and metabolic disorders.08-27-2009
20110081659SUBSTRATES FOR GLYCOGEN SYNTHASE KINASE 3 ENZYMES AND METHODS OF USE - Methods and compositions for glycogen synthase kinase 3 assays continue to be required for detection of glycogen synthase 3 kinase, assessment of glycogen synthase 3 kinase activity and identification of modulators of glycogen synthase 3 kinase. Methods and compositions for glycogen synthase kinase 3 assays are provided herein based on the discovery of a previously unknown interaction between glycogen synthase 3 kinase and eukaryotic translation initiation factor 4E-binding protein 1 which serves as a substrate for glycogen synthase kinase 3-alpha and glycogen synthase kinase 3-beta.04-07-2011
20110070595METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS - The present invention relates to immobilization compounds and methods useful for the identification of PARP interacting compounds or for the purification or identification of PARP proteins.03-24-2011
20110076693METHOD FOR DETECTION AND QUANTIFICATION OF PLK1 EXPRESSION AND ACTIVITY - Isolated peptide substrates of Plk1 and nucleic acids encoding these peptides are disclosed. The peptides include two to ten repeats of the amino acid sequence set forth as X03-31-2011
20110070594Method for Detecting Escherichia coli - Described herein are methods of detecting an infection and for detecting the presence or absence of microorganisms, for example, wound pathogens in a sample, by contacting a sample with an enzyme produced and/or secreted by the bacteria, and detecting modification or the absence of modification of the substrate, as an indicator of the presence or absence of the enzyme in the sample. The present invention also features a biosensor for detecting the presence or absence of bacteria in a sample.03-24-2011
20110065127Detection of Degradative Enzymes and Biomolecules in Bodily Fluids - Provided herein are methods, kits and compositions useful in detecting degradative enzymes and biomolecules in bodily fluid samples.03-17-2011
20120149031ANTI-CMET ANTIBODY AND ITS USE FOR THE DETECTION AND THE DIAGNOSIS OF CANCER - The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to antibodies capable of binding to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding processes, for detecting and diagnosing pathological hyperproliterative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the overexpression of cMet. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers.06-14-2012
20120149030IMMUNOASSAY FOR THROMBIN DETECTION - The invention relates to an in vitro immunoassay for quantifying thrombin in a sample comprising anti-thrombin III (AT-III) and thrombin. The method comprises the following steps: contacting the sample with a small molecule that recognizes the substrate binding site of thrombin; contacting the thrombin with a thrombin specific antibody raised against a thrombin blocked in the active site; and measuring the level of bound antibody.06-14-2012
20100297668HUMAN E3ALPHA UBIQUITIN LIGASE FAMILY - The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.11-25-2010
20090004675Method of Identifying Compounds for Bacterial Growth Modulation - The present invention relates to a method of identifying a candidate compound for modulating bacterial growth. This the method involves providing a β clamp peptide from a bacterial replicase, providing a second peptide that binds to at least one amino acid of SEQ ID NO:9 that is not designated X, wherein the second peptide does not exhibit polymerase activity, and providing a test compound. The β clamp peptide and the second peptide are contacted with the test compound, and the level of binding between the β clamp peptide and the second peptide in the presence of the test compound is determined. The level of binding between the β clamp peptide and the second peptide in the presence of the test compound is then compared to a control that does not contain the test compound. A test compound that alters the level of binding between the β clamp peptide and the second peptide compared to the control is a candidate compound for modulating bacterial growth.01-01-2009
20100015635IMMOBILISATION OF FLUORESCENT PROTEINS - The present invention concerns a method of detection of an analyte in which a protein capable of binding the analyte and comprising a fluorescent energy label and an energy acceptor moiety capable of accepting energy emitted by the label or protein by Forster energy transfer (FRET), is exposed to incident electromagnetic energy to excite the protein or label, and the fluorescent emission of the label is measured; characterised in that the protein is encapsulated in a biocompatible, optically transparent matrix which is permeable to the analyte, and in that the protein undergoes no substantial conformational change during the method; further characterised in that the energy acceptor moiety has a more active and less active state, which is determined by the presence of analyte, and the emission from the label is indicative of the presence of analyte. A biocompatible optically transparent matrix in which a protein capable of binding an analyte is also provided.01-21-2010
20110151481BETA-2 MICROGLOBULIN AS A BIOMARKER FOR PERIPHERAL ARTERY DISEASE - The present invention provides β2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.06-23-2011
20090253149Novel Chemistry Used in Biosensors - The invention relates to novel compositions and methods for the detection of analytes using the nuclear reorganization energy, λ, of an electron transfer process.10-08-2009
20120202219PSA CAPTURE AGENTS, COMPOSITIONS, METHODS AND PREPARATION THEREOF - Disclosed herein are novel synthetic prostate specific antigen (PSA)-targeted capture agents that specifically bind PSA. In certain embodiments, these PSA capture agents are biligand or triligand capture agents containing two or three target-binding moieties, respectively.08-09-2012
20120202218DETECTION METHOD AND DEVICE BASED ON NANOPARTICLE AGGREGATION - A method for determining the presence of a compound in a liquid solution, by admixing the liquid solution with a plurality of nanoparticles; providing conditions effective to cause aggregation of the nanoparticles in the liquid solution in the absence of said compound in the liquid solution; and observing a detectable signal reflecting the amount of aggregation of nanoparticles in the liquid solution, wherein the presence of the compound in the liquid solution results in a detectable signal reflecting a reduced amount of aggregation of nanoparticles in the liquid solution, in comparison to the amount of aggregation of nanoparticles obtained in the liquid solution in the absence of the compound therein. A nanoparticle, a composition, a kit and a for multi-well plate for use in the method are also disclosed. In some embodiments the association is cation-, anion and/or PH induced e.g. by using helix-loop-helix polypeptides as first and second molecules attached to the nanoparticles. The first molecules are directed to the target compound, the second molecules allow for aggregation of the nanoparticles.08-09-2012
20080213800Method for Examing Interstitital Cystitis - It has been found that the urine from an IC patient shows a high value in amount and the existence of activity of an azurophilic granular substance, thereby to establish a method for examining IC. The present invention relates to a method for examining interstitial cystitis using the kinetics of an azurophilic granular substance in urine as a marker. Also, the present invention relates to a kit for examining interstitial cystitis for use in the examination method, a use of an azurophilic granular substance as a test marker for examining interstitial cystitis or evaluating pharmacological effects of a drug, and a method for examining therapeutic effects on a patient with interstitial cystitis using an azurophilic granular substance as a marker.09-04-2008
20120276552SERUM SPLA2-IIA AS DIAGNOSIS MARKER FOR PROSTATE AND LUNG CANCER - Methods for diagnosing prostate cancer and lung cancer are disclosed. The methods include obtaining a biological sample from a subject, determining a level of serum secretory phospholipase A11-01-2012
20110053179Biomarkers For Prediction Of Major Adverse Cardiac Events And Uses Thereof - The present invention relates to combinations of biomarkers and levels thereof that may be used, for example, in the determination of risk associated with the occurrence of a major adverse cardiac event (MACE) in a patient.03-03-2011
20110053178Methods and Compositions for Detection of Lethal Cell and Uses Thereof - The present invention relates to methods and compositions for identifying and detecting lethal cell useful for monitoring disease status and therapy response in various types of cancer patients regardless of the etiological origin of the cancer and uses thereof.03-03-2011
20110053180KINASE SENSORS - The present invention generally relates to compositions and methods for determining kinase activity. In some cases, the compositions comprise a triazole heterocycle. In some embodiments, the compositions comprise a quinoline moiety. In one aspect, the present invention is directed to compositions that undergo chelation-enhanced fluorescence (CHEF). In some cases, the compositions may have fluorescence emission spectra with peak maxima greater than 490 nm. The compositions of the present invention can be used, in certain embodiments, to detect phosphorylated substrates and biological processes such as phosphorylation events.03-03-2011
20110027801EphA KINASE CANCER DIAGNOSTIC - A method of detecting malignant progression of neoplastic cells in an animal includes obtaining a sample of neoplastic cells from the animal, determining a level of S897-EphA2 phosphorylation in the neoplastic cells of the samplem, and comparing the determined level of S897-EphA2 phosphorylation in the sample to a control value, wherein an increased level of S897-EphA2 phosphorylation compared to the control value is indicative of malignant progression of the neoplastic cell in the animal.02-03-2011
20100285502NOVEL AROMATIC PRENYLTRANSFERASES, NUCLEIC ACIDS ENCODING SAME AND USES THEREFOR - In accordance with the present invention, a novel aromatic prenyltransferase, Orf2 from 11-11-2010
20110136138METHOD FOR PREDICTING A NEED FOR RENAL REPLACEMENT THERAPY (RRT) - A method for predicting a need for Renal Replacement Therapy (RRT) in a patient comprises: determining a concentration of pi glutathione S transferase-(πGST) in a first urine sample from the patient; and wherein a need for RRT is predicted when the πGST concentration is determined to be elevated in comparison to a patient without kidney injury. The method according to the invention can further comprise detecting for the presence of risk factors for RRT in a patient, the risk factors including elevated serum creatinine concentration, type I diabetes, type II diabetes, hypertension, dyslipidemia, hyperglycaemia, proteinuria and hypoalbuminemia.06-09-2011
20110136137SERUM PROTEOMIC FOR FINDING DIAGNOSTIC MARKERS AND FOR MONITORING THERAPEUTICAL INTERVENTION IN TREATMENT OF HEPATOCELLULAR CARCINOMA - The invention is directed to biomarkers for determining the EGFR kinase activity in a subject, and the use thereof for predicting and monitoring therapeutic intervention in cancer patients. Areas of application are the life sciences: biology, biochemistry, biotechnology, medicine and medical technology.06-09-2011
20110076692Detection of Cardiac Markers on a Droplet Actuator - The present invention provides for the detection of cardiac markers on a droplet actuator. An aspect provides a method of assaying a cardiac marker in a biological sample from a subject, the method including providing a droplet actuator, loading the biological sample and assay reagents on the droplet actuator, executing droplet operations to create sample droplets from the sample and reagent droplets from the reagents on the droplet actuator, and executing droplet operations using the sample droplets and reagent droplets to produce a detectable signal indicative of the quantity of the cardiac marker in the biological sample. Still other aspects are provided.03-31-2011
20100184088METHODS OF IDENTIFYING AGENTS THAT MODULATE METHYLATION OF VEGFR1 BY SMYD3 - The present invention relates to methods for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of VEGFR1 by SMYD3. The invention further provides methods and pharmaceutical compositions for treating and preventing colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified.07-22-2010
20100330588METHOD TO QUANTIFY METHYLTRANSFERASE ACTIVITY - The related disclosure pertains to a method to quantify methyltransferase activity. In an exemplar embodiment, the method may be carried out by the following steps: i) incubating a mixture comprising a methyltransferase, a substrate, and radiolabeled S-adenosylmethionine for a period of time sufficient for the protein methyltransferase to methylate and transform at least some of the substrate into a methylated product of the substrate, then ii) at one or more times removing an aliquot of the mixture, then iii) contacting the aliquot of the mixture to a resin capable of binding the methylated product of the substrate, followed by iv) a washing step to remove the unreacted radiolabeled S-adenosylmethionine, followed by v) an elution step to elute and isolate the methylated product, then vi) measuring the amount of radiolabel in the methylated product.12-30-2010
20100227335MATRIX METALLOPROTEINASE-7 (MMP-7) MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF OVARIAN CANCER - Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MMP-7. Monoclonal antibodies having the binding characteristics of an MMP-7 antibody of the invention and monoclonal antibodies that bind to an MMP-7 epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce an MMP-7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed MMP-7 monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MMP-7 epitope of a disclosed monoclonal MMP-7 antibody and methods of using these polypeptides in the production of MMP-7 antibodies are also encompassed by the present invention.09-09-2010
20100159480BIOSENSORS, METHOD FOR OBTAINING THE SAME AND USES THEREOF - The invention relates to biosensors, methods for obtaining them and their use for detecting, assaying or locating, in direct immunofluorescence, a ligand such as an antigen or hapten, in a heterogeneous population. The biosensor includes (i) at least one fragment of a receptor which is protein in nature, capable of binding to a ligand via an active site, where at least one amino acid residues of the fragment located in the proximity of the active site is naturally present in the form of a cystein (Cys) residue, or is substituted with a Cys residue, and (ii) a fluorophore coupled to the Cys residue.06-24-2010
20100159478BIOMARKERS FOR CHRONIC VASCULAR DYSFUNCTION - Materials and methods for using biomarkers to determine prognosis and response to treatment in subjects having chronic vascular dysfunction.06-24-2010
20100159481DETECTION OF HYPERTENSION USING GLUCURONIDATED METABOLIC PRODUCTS - A method of assessing arachidonic acid (AA) metabolites-dependent hypertension by measuring glucuronidated dihydroxyeicosatrienoic acids (DHETs) and DHET metabolites in a biological sample which contains the epitopes unique to DHET (using any methods including GC/MS, LC/MS or ELISA). An example of the glucuronidated DHET metabolite is DHET-alcohols such as omega or omega-1 oxidated DHET and DHET esterified glycerol. The method further includes determining the amount of glucuronidated molecules containing a DHET-specific epitope which is immunoreactive with antibodies produced against DHETs.06-24-2010
20100196926Combined Method And Kit For The Sequential Measurement of (1) The Enzymatically Active Fraction And (2) The Total Amount Of An Enzyme - The present invention is related to a combined method and kit (or device) for the sequential measurement of the enzymatically active fraction and the total amount of an enzyme [(such as myeloperoxidase (MPO)] in a sample, and that find improved applications in veterinary and human health fields.08-05-2010
20120178101DEVICE, METHOD, AND SYSTEM FOR QUANTITATIVELY MEASURING A SPECIMEN USING A CAMERA - The present invention relates to a device and method for quantitatively measuring an analyte using a camera. More particularly, to capture the identification code required for obtaining an accurate analysis result for the analyte to be analyzed, to capture the result of the reaction of the analyte using a camera without additional equipment, and to read the identification code and the result of the reaction of the analyte, the device of the present invention comprises: a camera for capturing a camera recognition area of an analyte kit, which contains an analyte reaction result obtained by the reaction of the analyte and an identification code for the analyte kit; an image-processing unit for separating the analyte reaction result image and the identification code image from images of the camera recognition area of the analyte kit captured by the camera; a reading unit for reading the analyte reaction result image and the identification code image; and a control unit for enabling the read result of the analyte reaction result image to be processed using the read result of the identification code image.07-12-2012
20090203044SPHINGOSINE-1-PHOSPHATE LYASE POLYPEPTIDES, POLYNUCLEOTIDES AND MODULATING AGENTS AND METHODS OF USE THEREFOR - Compositions, methods and kits for diagnosing and treating cancer are provided. Therapeutic compositions may comprise agents that modulate the expression or activity of a sphingosine-1-phosphate lyase (SPL). Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous SPL. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided.08-13-2009
20090142776ANTIBODY FOR ASSAYING ADAMTS13 ACTIVITY AND METHOD FOR ASSAYING THE ACTIVITY - The subject of the present invention is to provide a useful antibody for measuring ADAMTS13 activity, in particular, a monoclonal antibody and a method for measuring ADAMTS13 activity. Further, another subject of the present invention also is to provide a monoclonal antibody which has specific reactivity to an antigenic determinant site produced by reacting ADAMTS13 with VWF that is a substrate or a partial peptide of VWF that is a potential substrate, but has no specific reactivity to the complete VWF molecule, and a use of the antibody of interest. Those subjects were achieved by succeeding in obtaining a monoclonal antibody (anti-N-10 monoclonal antibody) which has specific reactivity to a cleavage site that is cleavable by ADAMTS13 in the partial peptide of VWF, and further by finding a method for measuring ADAMTS13 activity using the monoclonal antibody of interest.06-04-2009
20100136578METHOD OF MEASURING THE ACTIVITY OF LIPID-MODIFIED ENZYME - It is intended to provide an assay method whereby the activity of a lipid-modifying enzyme can be conveniently measured over a wide range and a drug capable of controlling a lipid-modifying enzyme with the use of this assay method. The above problem can be solved by, for example, a method of measuring the activity of a lipid-modifying enzyme which comprises the steps of (I) preparing a lipid micelle containing a biotinylated lipid and a substrate for the lipid-modifying enzyme; (II) bringing the lipid micelle prepared in the above step (I) into contact with the lipid-modifying enzyme; and (III) evaluating the activity of the lipid-modifying enzyme by applying an evaluation method using the proximity effect to the product obtained in the above step (II).06-03-2010
20110189698Protein Biomarkers and Methods for Diagnosing Kawasaki Disease - A method, kit and device for diagnosing Kawasaki Disease are provided. The invention provides detecting an expression level of at least two Kawasaki Disease diagnostic biomarkers in a biological sample from a patient with a capture agent and diagnosing the patient as having Kawasaki Disease when the expression levels of the at least two diagnostic biomarkers in the patient biological sample are higher than the normal expression levels of the same biomarkers in a biological sample from a control subject. The first Kawasaki Disease diagnostic biomarker disclosed in the present invention is a cardiomyocyte biomarker, and the second Kawasaki Disease diagnostic biomarker is an inflammatory biomarker. The invention further provides detecting an expression level of a third biomarker, interferon type-I biomarker, in the patient biological sample with a capture agent and diagnosing the patient as having Kawasaki Disease when the expression level of interferon type-I biomarker is lower than the expression level in a control subject.08-04-2011
20110189697RECOMBINANT CELLS AND PLANTS FOR SYNTHESIS OF VERY LONG CHAINS FATTY ACID (VLCFA) - The present disclosure is relative to a method for the production of Very-Long-Chain Fatty Acids (VLCFA) into a plant cell, including culturing a recombinant plant cell in an appropriate medium, wherein said plant cell is transformed with an heterologous gene encoding for an hydroxyacyl-CoA dehydratase. The disclosure is also relative to a method for producing vegetable oil including high levels of VLCFA.08-04-2011
20120309020LYSYL OXIDASE-LIKE 2 ASSAY AND METHODS OF USE THEREOF - The present disclosure provides an assay to detect and/or quantify circulating lysyl oxidase-like 2 (LOXL2) polypeptides in an individual. The assay is useful in diagnostic and prognostic applications, which are also provided.12-06-2012
20120309018CANCER DETECTION MARKERS - Methods and compositions involving molecular markers for the detection and characterization of cancer in a patient are provided.12-06-2012
20100028907Novel Antigens and Antibodies Associated to Pancreatic Ductal Adenocarcinoma - The present invention provides novel human protein antigens and related antibodies that have been identified as being specifically expressed in association to human Pancreatic Ductal Adenocarcinoma (PDA). In particular, novel phosphorylated isoforms of alpha-enolase have been identified in transformed cell lines of pancreatic origin and antibodies binding such isoforms are specifically present in the sera of PDA patients. These proteins and antibodies can be useful for the diagnosis and the treatment of PDA and other cancers having common molecular features.02-04-2010
20100021939PROCESS FOR DETECTING ENZYME ACTIVITY IN AN IMMUNOASSAY - The invention relates to a process for detecting enzyme activity in an immunoassay comprising the following steps:01-28-2010
20120040371DIAGNOSIS OF PREECLAMPSIA - The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia.02-16-2012
20120040372RECEPTOR TYROSINE KINASE ASSAYS - Methods for detecting phosphorylation of receptor tyrosine kinases (“RTKs”) upon activation and the modulation of activation by a candidate compound are provided. The method employs cells comprising two fusion products: (1) an RTK fused to a small fragment of β-galactosidase and (2) a phosphotyrosine binding peptide fused to the large fragment of β-galactosidase, where the 2 fragments weakly complex to form an active enzyme, and optionally a construct for a cytosolic RTK phosphorylating kinase, when the RTK does not autophosphoryate. To detect phosphorylation a β-galactosidase substrate is added to the cells, whereby product formation indicates the occurrence of phosphorylation.02-16-2012
20110143368Tyrosine phosphorylation sites - The invention discloses 142 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.06-16-2011
20100221747IMMUNOCHROMATOGRAPHY DETECTION OF MULTIDRUG-RESISTANT STAPHYLOCOCCUS AND DIAGNOSTIC KIT - It is intended to provide an immunochromatographic detection device which detects PBP2′ specifically produced by a multidrug-resistant 09-02-2010
20110306060PCSK9 IMMUNOASSAY - Methods of using PCSK12-15-2011
20100081147HUMAN CATECHOL-O-METHYLTRANSFERASE (COMT) ASSAY - Disclosed is an assay (method) to quantify the amounts of catecholamine-O-methyltransferase (COMT) protein in samples, such as extracts from cell cultures, body fluids, tissues, and environmental samples. It uses novel agents (anti-NE, COMT-NE, or COMT-epitope-NE) in combination with two previously described agents (anti-COMT and COMT) in a competitive ELISA system to achieve this aim.04-01-2010
20100221748AMPK modulation as a method of regulating stem cell and cancer stem cell proliferation, self-renewal and differentiation - Methods are disclosed for decreasing stem cell proliferation, including cancer stem cell proliferation. These methods comprise administering to stem cells inhibitors of AMP activated protein kinase (AMPK). Methods for promoting stem cell growth by increasing stem cell proliferation, self-renewal and/or differentiation are also disclosed. These methods comprise administering AMPK activators to stem cells. Methods of achieving selective differentiation of stem cells are also disclosed. These methods comprise administering small molecules to stem cells that modulate AMPK activity. Applications of these methods are also disclosed, such as methods of increasing numbers of neuronal progenitor cells. These methods can be used therapeutically, such as for repair of spinal cord injuries, or for stimulating neurogenesis in the hippocampus, and other cell-based therapies. The methods can also be used for screening of compounds that can be activators or inhibitors of AMPK activity.09-02-2010
20110306059COMPOSITIONS AND METHODS FOR MEASURING 3,6-L-AHG TRANSFERASE ACTIVITY AND 3,6-L-AHG - Provided herein are a composition for measuring 3,6-anhydro-L-galactose (3,6-L-AHG) transferase activity by reduction of NADP to NADPH, and a method of measuring 3,6-L-AHG transferase activity using the same. The composition and method are useful for determining 3,6-L-AHG in a material containing 3,6-L-AHG such as algae biomass and industrial applications.12-15-2011
20110111427BIOMARKER FOR THE ESTIMATION OF ACUTE RENAL DISORDER AND PROGNOSIS OF THE DISORDER, AND USE OF THE BIOMARKER - To provide a novel biomarker that is useful for prediction of early onset of acute kidney injury, estimation of prognosis associated with a renal function, and differentiation of acute kidney injury. Furthermore, to provide use of the novel biomarker. Midkine is used as a biomarker. The determination of a possibility of the onset of acute kidney injury, estimation of prognosis associated with a renal function or differentiation of an acute kidney injury are carried out based on the detection result of the urinary midkine.05-12-2011
20100311081PREDICTING CANCER PROGRESSION - A method of predicting the likelihood of cancer relapse in a patient undergoing treatment for cancer is provided. The binding response level of an immunoreactive material (IM) comprising thymidine kinase 1 (TK1) protein is determined in a body fluid sample of a patient and the likelihood of relapse of the cancer disease is predicted based on this determined IM binding response level. Those patients that run a risk of cancer progress and relapse 1-15 years after the cancer treatment may be identified directly by the IM binding response level within a few months following initiation of the treatment.12-09-2010
20100317030METHODS AND COMPOSITIONS FOR DETERMINING ENZYMATIC ACTIVITY - The present invention comprises crystalline polyketide synthases, isolated non-native polyketide synthases having the structural coordinates of said crystalline polyketide synthases, and nucleic acids encoding such non-native polyketide synthases. Also disclosed are methods of predicting the activity and/or substrated specificity of putative polyketide synthase, methods of identifying potential polyketide synthase substrates, and methods of identifying potential polyketide synthase inhibitors.12-16-2010
20120309019DETECTION OF UNHEALTHY BONE MARROW-DERIVED CELL FOR DISEASE PREDISPOSITIONS - Provided herein is a method for detecting the presence of a unique subset of unhealthy bone marrow-derived cell (BMDC) by co-staining the cytoplasmic and/or nuclear expression of PDPK F12-06-2012
20090053737Monoclonal Antibody Which Binds Met In Formalin-Fixed and Paraffin-Embedded Tissues and Related Methods - In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.02-26-2009
20100047824CITRUS FRUIT PEELING PROCESS - An efficient process for enzymatically peeling citrus fruit applies a vacuum to perforated fruit and, while maintaining that vacuum, introduces an enzyme solution to the perforated fruit. The fruit is infused with the enzyme by releasing the vacuum pressure. After incubating the enzyme, the albedo of the fruit is weakened and the citrus peel can be readily removed. The peeled fruit may be divided into sections and the encompassing membrane removed.02-25-2010
20120045774Lipoprotein Associated Phospholipase A2, Inhibitors Thereof and Use of the Same in Diagnosis and Therapy - The enzyme Lp-PLA02-23-2012
20120045775PHOSPHOSPECIFIC PAK ANTIBODIES AND DIAGNOSTIC KITS - The present invention relates to the use of phosphorylated p21-activated protein kinases (PAK), especially PAK4, as biomarkers of tumorogenesis. The present invention contemplates the use of phosphospecific antibodies for detecting phosphorylated PAK from mammalian biopsies, as well as screening assays for identifying compounds that modulate PAK activity. Also contemplated is a method for determining a subset of a given population that is amenable to treatment with a compound that modulates PAK activity.02-23-2012
20120003665Dissolved Protein Arthritis Markers - Methods and kits for diagnosing arthritis are provided. The methods may involve detection of 14-3-3 eta or gamma proteins in a sera or synovial fluid sample.01-05-2012
20120208209PCSK9 IMMUNOASSAY - Methods of using PCSK9 antagonists. More specifically, methods for measuring circulating PCSK9 levels in a biological sample by means of an immunoassay.08-16-2012
20120208208PCSK9 IMMUNOASSAY - Methods of using PCSK9 antagonists. More specifically, methods for measuring circulating PCSK9 levels in a biological sample by means of an immunoassay.08-16-2012
20120009594METHOD FOR MEASURING BETA-GLUCAN, AND BETA-GLUCAN-BINDING PROTEIN FOR USE IN THE METHOD - Disclosed are a method for measuring βG comprising the steps of bringing a sample into contact with a βG-binding protein 1 and a βG-binding protein 2, each comprising an amino acid sequence which is identical or substantially identical to an amino acid sequence shown in any one of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20, and having the β-glucan binding activity, to form a complex of the βG-binding protein 1, βG in the sample and the βG-binding protein 2, measuring quantity of the complex, and determining βG concentration in the sample based on the quantity of the complex; a reagent and a kit for use in said method; a novel βG-binding protein; a nucleic acid molecule encoding the βG-binding protein; and a method for producing the aforementioned βG-binding protein.01-12-2012
20120009593ANALYSIS METHOD FOR THE IN VITRO DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN DOGS BY ASSAYING CANINE PROSTATE SPECIFIC ESTERASE, AND BPH TREATMENT FOLLOW UP - The invention relates to an analysis method for the in vitro diagnosis of benign prostatic hyperplasia (BPH) in a dog, using the CPSE contained in biological fluid samples collected from the dog as well as biological molecules specifically binding CPSE. The invention is characterised in that it includes the following steps: a. collecting a biological fluid sample from a dog; b. measuring the canine prostate specific esterase (CPSE) of said sample; c. comparing said measured CPSE concentration with a reference value, said value being from around 34 ng/ml to around 102.4 ng/ml for serum or plasma, preferably around 61 ng/ml; d. using the CPSE concentration as a BPH marker; and e. diagnosing BPH in a dog when measured CPSE concentrations in said sample exceed said reference value.01-12-2012
20110165594SYSTEMIC MARKERS FOR ASTHMA AND ANALOGOUS DISEASES - Provided herein are diagnostic and prognostic methods, diagnostic and prognositic markers, and methods for evaluating anti-inflammatory agents or drugs in subjects with asthma and/or an analogous disease associated with high oxidative and nitrative stress at the disease site. In certain embodiments, the methods comprise a step of assaying for decreased levels of superoxide dismutase activity in the blood, serum, or plasma of the subject. In certain embodiments, the methods comprise a step of assaying for elevated levels of one or more oxidatively-modified SOD isoforms or species in the blood, serum or plasma of the subject. Also provided are diagnostic kits for use in the present invention. In certain embodiments, such kits comprise at least one binding reagent that specifically binds to at least one oxidatively-modified SOD species.07-07-2011
20110165593Mutants of 06-Alkylguanine-DNA Alkyltransferase - The invention relates to AGT mutants showing, when compared to the wild type human AGT, two or more advantageous properties selected from (a) reduced DNA interaction; (b) localisation of the expressed protein in eukaryotic cells that is no longer restricted to the nucleus; (c) improved expression yield as soluble protein and improved stability in various hosts; (d) improved stability under oxidising conditions; (e) improved stability within cells after reaction with a substrate; (f) improved stability outside cells before and after reaction with a substrate; (g) improved in vitro solubility; (h) improved reactivity against O07-07-2011
20120115165BIOMARKERS FOR DETECTION AND DIAGNOSIS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA - Novel, sensitive and specific markers and methods for diagnostics and monitoring of head and neck squamous cell carcinoma (HNSCC) are provided. Kits and methods for the use of hyaluronic acid, hyaluronidase and CD44 to diagnose HNSCC are described.05-10-2012
20120064542MONOCLONAL ANTIBODIES AND DETECTION METHODS FOR ENZYMES THAT CONFER RESISTANCE TO 2,4-DICHLOROPHENOXYACETIC ACID - Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of AAD-1 (aryloxyalkanoate dioxygenase) enzyme. These monoclonal antibodies are surprisingly well suited for detecting AAD-1 transgenic event gene products in a variety of plants and plant tissues. The invention further provides quantitative and qualitative immunoassays using the immunoglobulins of the invention.03-15-2012
20090011431Diagnosis of Sepsis by the Selective Determination of the Concentration of Cu/Zn Superoxide Dismutase (Cu/Zn Sod) in Patient Samples - The present invention relates to a method for the early determination of the risk of mortality of patients in intensive care units or emergency care units during which the concentration of Cu/Zn superoxide dismutase (Cu/Zn SOD) in a serum sample or plasma sample of the patient is selectively determined, and quantitatively or semi-quantitatively measured concentrations, which exceed a predetermined threshold value are correlated with a high risk of mortality.01-08-2009
20120156691COMPOUND - Alternative methods for the detection and measurement of proteases in biological samples and compounds which allow for such detection are required to allow for rapid and selective identification of these enzymes. Compounds which allow for selective identification of these enzymes are provided with assays and kits for their use.06-21-2012
20120156692METHOD FOR SELECTING MARKER FOR DIAGNOSIS OF NUTRITIONAL STATUS OF PLANT, METHOD FOR DIAGNOSING NUTRITIONAL STATUS OF PLANT, AND METHOD FOR DETERMINING GROWTH STATUS - The present invention provides a method for selecting a marker for diagnosis of the nutritional status capable of reflecting the status of a particular nutrient in a plant without being influenced by various stresses in environmental factors, etc., and a method for diagnosing the status of a particular nutrient in a plant using a marker for diagnosis of the nutritional status selected by the method. A metabolite quantitatively changed depending on only the amount of a particular nutrient in a plant is selected as a marker for diagnosis of the nutritional status reflecting the status of the nutrient in the plant.06-21-2012
20100055715Nucleic and amino acid sequences of prokaryotic ubiquitin-like protein and methods of use thereof - The present invention relates to prokaryotic ubiquitin-like protein (Pup) nucleic acid sequences and Pup amino acid sequences encoded therefrom. Also encompassed are antibodies that are immunologically specific for Pup. Methods directed to isolation and identification of pupylated substrates that utilize the conjugated Pup as an affinity tag are also included. Pupylated substrates that are identified using the method and reagents of the present invention provide tools useful for the identification of additional components of prokaryotic proteasomal machinery. Modulators of Pup activity and methods for identifying such modulators are also encompassed herein.03-04-2010
20120156690METHOD FOR DIAGNOSING HEMANGIOSARCOMA IN CANINE USING DETECTION OF THYMIDINE KINASE ACTIVITY - The disclosure relates to a method for detecting hemangiosarcoma in canines. The method includes the steps of: (1) obtaining a quantity of blood from the subject canine; (2) separating the quantity of blood into a serum portion and a non-serum portion; (3) contacting the serum portion of the blood with a detector to detect presence of an amount of Thymidine Kinase (TK); and (4) detecting the level of TK in serum and determining whether TK is present in amounts of about 8 units/L or greater.06-21-2012
20120122117SECRETED PHOSPHOLIPASE A2 BIOMARKERS FOR ARTHRITIS - The present invention relates to the use of protein expression profiles of sPLA2 isoforms with clinical relevance to osteoarthritis (OA). In particular, the invention provides methods for diagnosing OA or determining risk factors for development of OA based on expression of sPLA2-IIA.05-17-2012
20120122116USE OF LYMPHOCYTES TO MEASURE ANTHRAX LETHAL TOXIN ACTIVITY - It is disclosed herein that isolated lymphocytes, such as human B-cells and CD405-17-2012
20110104712Method for Assaying Plasma Enzymes in Whole Blood - The present invention relates to a method for assaying catalytic plasma enzymes, such as transaminases and NADH-dependent enzymes, in a sample of whole blood, by measuring, in a microfluidic chamber, the decrease in the fluorescence of NADH consumed during the enzymatic reactions catalyzed by the NADH-dependent enzymes.05-05-2011
20120135421METHODS FOR THE IDENTIFICATION OF PHOSPHATIDYLINOSITOL KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF PHOSPHATIDYLINOSITOL KINASE PROTEINS - The present invention relates to immobilization compounds of formula (I), immobilization products and preparations thereof as well as methods and uses for the identification of phosphatidylinositol kinase interacting compounds or for the purification or identification of phosphatidylinositol kinase proteins.05-31-2012
20120315649METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 10B, Cadherin-16, Caspase-9, Bcl2 antagonist of cell death, Caspase-1, Cadherin-1, Poly [ADP-ribose] polymerase 1, Cyclin-dependent kinase inhibitor 1, Cadherin-5, Myoglobin, Apolipoprotein A-II, Mucin-16, Carcinoembryonic antigen-related cell adhesion molecule 5, and Cellular tumor antigen p53 as diagnostic and prognostic biomarker assays in renal injuries.12-13-2012
20110003312LINKED PEPTIDE FLUOROGENIC BIOSENSORS - Biosensors, compositions comprising biosensors, methods of producing biosensors, and methods of using biosensors are disclosed. The biosensors comprise a fluorogen-activating peptide and a blocking peptide. The fluorogen-activating peptide and blocking peptide are covalently linked through a peptide linker. The blocking peptide associates with the fluorogen-activating peptide thereby blocking an active domain of the fluorogen-activating peptide when the linker is in an unmodified state. The peptide linker may contain an amino acid sequence that is specifically recognized as a modification substrate by a cognate enzyme. The fluorogen-activating peptide and the blocking peptide at least partially disassociate when the linker is modified by an enzyme, thereby allowing the fluorogen-activating peptide to bind a cognate fluorogen and modulate a fluorescence signal.01-06-2011
20100248264Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions - Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Automated systems for performing the methods also are provided.09-30-2010
20110183357DEVICE AND METHODS FOR LIQUID CRYSTAL-BASED BIOAGENT DETECTION - The present invention provides liquid crystal-based devices and methods for bioagent detection. In certain aspects, the present invention is directed to devices and methods utilizing liquid crystals and membranes containing polymerized targets that can report the presence of bioagents including, but not limited to, enzymes, antibodies, and toxins.07-28-2011
20120129186DEVICES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF WOUNDS USING BIOMARKERS - The present invention provides for devices and methods for determining the healing phase of a wound. In some aspects, the present invention provides a wound diagnosis device comprising a surface and at least one agent that is specific to a desired biomarker. In another aspect, the present invention provides a method of determining the phase of wound healing. In still other aspects, the present invention provides methods of determining the phase of wound healing using the disclosed devices.05-24-2012
20120129185METHODS AND COMPOSITIONS FOR DIAGNOSING ANKYLOSING SPONDYLITIS USING BIOMARKERS - The invention provides a method for determining the efficacy of a TNFα inhibitor, such as a TNFα antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker.05-24-2012
20120129187DIAGNOSTICAL USE OF PEROXIREDOXIN 4 - The present invention relates to a method for the diagnosis or prognosis of a disease or clinical condition in a subject comprising the steps of: (i) providing a sample of bodily fluid of a subject, (ii) determining the level of peroxiredoxin 4 (PRX4) or a fragment thereof having at least 20 amino acids residues in length in said sample, and (iii) correlating the level of PRX4 or a fragment thereof with a disease or clinical condition.05-24-2012
20100209943Measurement Of Protease Activity In Post-Mortem Meat Samples - The present methods and systems relate to the placement on meat surfaces of a dye-linked protease substrate bonded in a defined location to a solid, porous support. Proteases in the meat hydrolyze the substrate, which then releases the dye, which diffuses away so that the extent of diffusion can be determined by imaging. Alternatively, the amount of dye released can be determined by its mobilization into a liquid medium. The present methods and systems also relates to determining the amount of hydrolyzed protein that is present in post-mortem meat samples. Agents which bond to hydrolyzed proteins, but not to unhydrolyzed proteins, are generated, wherein such agents comprise antibodies or aptamers. Such agents are then used in quantitative assays comprising ELISA tests or lateral flow tests.08-19-2010
20100209942NEW BIOMARKER FOR MONITORING DEVELOPMENT OF DISEASES AND ASSESSING THE EFFICACY OF THERAPIES - The invention concerns a method for monitoring the development of a disease in a patient, or for assessing the efficacy of a cytokine therapy or a statin therapy in a patient, in which methods CD73 in a tissue fluid drawn from said patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid.08-19-2010
20120315650DETECTION OF CIRCULATING ADAMTS13-ANTIBODY COMPLEXES - The present invention relates to methods and means for detecting ADAMTS13 immune complexes in a sample. The methods include the steps of capturing and labelling immune complexes of anti-ADAMTS13 antibodies. Capturing and labelling may be achieved by two different binding units targeting the immune complexes. The invention further relates to diagnosing diseases associated with immunologic ADAMTS13 dysfunction like TTP (thrombotic thrombocytopenic purpura).12-13-2012
20120171696Gene Defects And Mutant ALK Kinase In Human Solid Tumors - In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.07-05-2012
20120077209PROTEIN BIOMARKERS AND THERAPEUTIC TARGETS FOR AUTOIMMUNE AND ALLOIMMUNE DISEAES - A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value.03-29-2012
20120219963DERIVATIVES OF URIDINE PHOSPHATE AND THEIR USES IN PROTEIN BINDING ASSAYS - The present invention relates to compounds and their use in competitive protein binding assays, for example for use with glycosyl transferase and/or glycoprocessing proteins. The present application also provides kits and apparatuses for use in the assays. In particular, the present invention provides a compound of the formula (I): wherein n is 1, 2 or 3; R08-30-2012
20120178100Serum Markers Predicting Clinical Response to Anti-TNF Alpha Antibodies in Patients with Psoriatic Arthritis - The invention provides tools for management of patients diagnosed with psoriatic arthritis, specifically, prior to the initiation of therapy with an anti-TNFα agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary endpoints using serum marker concentrations. In one embodiment the baseline levels of VEGF, prostatic acid phosphatase, and adiponectin are used to predict the response at Week 14 after the initiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as MDC, lipoprotein a, and beta2-microglobulin.07-12-2012
20100273187ANTIBODIES AGAINST DELTA-5 DESATURASE AND USES THEREOF - Disclosed are antibodies that specifically recognize Δ5-desaturase, methods of producing the antibodies, nucleotides and polypeptides for producing the antibodies, and methods of using the antibodies. The Δ5-desaturase-specific antibodies provide improved methods of detecting Δ5-desaturase in a sample.10-28-2010
20100273186SPLIT MUTANT HYDROLASE FUSION REPORTER AND USES THEREOF - The invention provides polynucleotides encoding and polypeptides corresponding to split hydrolase fusion proteins, wherein the hydrolase sequence may include at least one substitution, and use of the split hydrolase fusion proteins.10-28-2010
20100240068MARKER PANEL FOR COLORECTAL CANCER - The present invention relates to a method for assessing colorectal cancer (CRC) in vitro including measuring in a sample the concentration and/or activity of a seprase polypeptide and/or fragments thereof and of either anti-p53 and/or osteopontin and/or ferritin, of optionally one or more other marker of CRC, and using the combined measurement result in the assessment of CRC. Furthermore, it especially relates to a method for assessing CRC from a liquid sample, derived from an individual by measuring seprase and at least anti-p53, ferritin and/or osteopontin in the sample. The method according to the present invention can, e.g., be used in the early detection of cancer by screening of asymptomatic individuals or in the surveillance of patients who undergo surgery.09-23-2010
20100291591NOVEL PLATING MEDIA - Plating media contains enzyme substrates (ES) used to detect enzyme activity associated with a target organism and that include a binding motif (BM) that serves to bind detectable enzymes (DE) (also called marker enzymes in this disclosure). A signalogenic substructure (SG) produces detectable signals and an enzyme labile group (ELG) is labile to the action of a marker enzyme and it typically includes the binding motif. The enzyme labile group links to the signalogenic substructure via a labile bond (LB) which is cleaved by the action of the marker enzyme separating the signalogenic substructure and the enzyme labile group. In some embodiments a linker is inserted between the signalogenic substructure and the enzyme labile group. Presence of the enzyme and thus the organism is detected by presence of a fluorogenic, precipitate that can be detected in single colonies.11-18-2010
20100291590METHODS FOR THE DIAGNOSIS AND THE PROGNOSIS OF A BRAIN TUMOR - The present invention relates to methods for the diagnosis of a brain tumor and for the estimation of a prognosis for patients having a brain tumor using the presence/absence of a particular IDH1 mutation as a marker.11-18-2010
20120264139METHOD FOR DIAGNOSING ACUTE CORONARY SYNDROME - This invention concerns a bioaffinity assay for quantitative determination in a sample of free PAPP-A, defined as the pregnancy associated plasma protein A (PAPP-A) that is not complexed to the proform of major basic protein (proMBP), wherein10-18-2012
20120082999NEW ANTIBODY COCKTAIL - The present invention relates to a composition comprising at least three primary antibodies or fragments thereof, wherein the at least three antibodies or fragments thereof binds specifically to at least three different proteins, and wherein the at least three different proteins are AMCAR, CK 5/6, and HMWC. Methods for using the composition in diagnosis, prognosis, and assessing efficacy of treatment is further included as well as kits comprising said composition, and optionally, instructions of its use.04-05-2012
20120258469Methods And Devices For Using Mucolytic Agents Including N-Acetyl Cysteine (NAC) - Devices and methods incorporate mucolytic agents into a point-of-care testing device. The sample is loaded, and then the sample travels until it encounters one or more lysis agents and/or mucolytic agents. The mucolytic agent is preferably pre-loaded onto the collection device. In a preferred embodiment, the mucolytic agent is localized between the sample application zone and the conjugate zone. In embodiments with a sample compressor, one or more mucolytic agents may be pre-loaded and dried on the sample compressor, the sample collector, in various locations on the test strip, or in the running buffer.10-11-2012
20120190043ENZYMATIC SUBSTRATES FOR MULTIPLE DETECTION SYSTEMS - An inventive substrate is provided which includes a substrate compound of formula A-B07-26-2012
20120190044METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of metalloproteinase inhibitor 2, soluble oxidized low-density lipoprotein receptor 1, interleukin-2, von Willebrand factor, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor receptor superfamily member 11B, neutrophil elastase, interleukin-1 beta, heart-type fatty acid-binding protein, beta-2-glycoprotein 1, soluble CD40 ligand, coagulation factor VII, C—C motif chemokine 2, IgM, CA 19-9, IL-10, TNF-α, and myoglobin as diagnostic and prognostic biomarkers in renal injuries.07-26-2012
20120190042PROTEIN BIOMARKERS AND THERAPEUTIC TARGETS FOR OSTEOARTHRITIS - The present invention relates to the identification and use of protein expression profiles with clinical relevance to osteoarthritis. In particular, the invention provides the identity of marker proteins whose expressions are correlated with OA, and/or OA progression. Methods and kits are described for using these protein expression profiles in the study and/or diagnosis of OA, in the determination of the degree of advancement of OA, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that modulate expression of these proteins or nucleic acid molecules encoding these proteins, in particular for the development of disease-modifying OA agents.07-26-2012
20090017467COMPOSITION EXHIBITING A VON WILLEBRAND FACTOR (vWF) PROTEASE ACTIVITY COMPRISING A POLYPEPTIDE CHAIN WITH THE AMINO ACID SEQUENCE AAGGILHLELLV - The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.01-15-2009
20110124009COMPOSITION, KIT AND METHOD FOR ASSAYING NEUROPATHY - The present invention relates to a method for detecting a disease accompanied with neuropathy such as glaucoma, comprising measuring and/or detecting one or more of polypeptides shown in SEQ ID NOS: 1 to 15, mutants thereof, or fragments thereof in a biological sample from a subject, and also to a composition or kit for diagnosis of a disease accompanied with neuropathy such as glaucoma.05-26-2011
20080299584ONCOPROTEIN PROTEIN KINASE ANTIBODY KIT - An isolated polypeptide (JNK) characterized by having a molecular weight of 46 kD as determined by reducing SDS-PAGE, having serine and threonine kinase activity, phosphorylating the c-Jun N-terminal activation domain and polynucleotide sequences and method of detection of JNK are provided herein. JNK phosphorylates c-Jun N-terminal activation domain which affects gene expression from AP-1 sites.12-04-2008
20120264138METHOD FOR DIAGNOSING AND MONITORING CARDIAC ISCHEMIA IN PATIENTS WITH ACUTE CHEST PAIN AND WITHOUT MYOCARDIAL INFARCTION - The present disclosure relates to a method for diagnosing the ischemic state in a subject suffering from acute coronary syndrome who does not fulfilling the diagnostic criteria for a myocardial infarction. The present disclosure also relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome but does not fulfill the diagnostic criteria for a myocardial infarction. The methods of the present disclosure are based on the determination of fms-like tyrosine kinase-1 (sFLT-1) and, optionally, hepatocyte growth factor (HGF) in a sample of said subject. The present disclosure also relates to kits and/or devices for carrying out the methods disclosed herein.10-18-2012
20120322080Measurement of PKA for Cancer Detection - The present invention relates to a method of detecting the presence of cancer by measuring the level of enzyme activity and autoantibodies in the blood of an individual. In particular the present invention relates to methods for measurement of activated cAMP-dependent protein kinase A (PKA) activity and antibodies to PKA, a kit for activated PKA activity measurement, and the use of the measured levels of these analytes for determining the presence of cancer.12-20-2012
20120322081METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN - Provided herein is a large immuno-sorbent surface area assay (ALISSA) for rapid and sensitive detection of toxin or enzyme activity. This assay is designed to capture a low number of toxin or enzyme molecules and to measure their intrinsic protease activity via conversion of a fluorigenic or luminescent substrate. The ALISSA is significantly faster and more sensitive than methods routinely utilized in the art. This assay is applicable for use for detection of a variety of toxins or enzymes having proteolytic activity, such as 12-20-2012
20100159479TIMP-1 AS A MARKER FOR COLORECTAL CANCER - The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein TIMP-1 (tissue inhibitor of metalloproteinase 1) as a marker molecule in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual, the method involving measuring TIMP-1 in the sample. Measurement of TIMP-1 can, e.g., be used in the early detection or diagnosis of colorectal cancer.06-24-2010
20120270234DDR2 PROTEIN WITH ACTIVATED KINASE ACTIVITY AND PREPARATION METHOD THEREOF - The present invention relates to a protein containing a modified DDR (Discoidin Domain Receptor) 2 cytosolic tyrosine kinase domain having an increased autophosphorylation and tyrosine kinase activity; a method for preparing a large amount of a protein containing DDR2 cytosolic tyrosine kinase domain, having an increased autophosphorylation and tyrosine kinase activity by inducing phosphorylations of tyrosines by a co-expression with Src or Src related proteins in host cells, or by H2O2 processing of host cells, or a site directed mutation modifying at least one of tyrosines to other amino acid; and a use thereof as a target material in developing medical drugs for treating a disease caused by an excessively activated DDR2 autophosphorylation and tyrosine kinase activity.10-25-2012
20120270233ASSOCIATION OF BIOMARKERS WITH PATIENT OUTCOME - The present method relates to quantification of prognostic and predictive biomarkers of the PDK/AKT/mTOR pathway, such as GSK3β, S6, CREB, PTEN, AKT and mTOR, using AQUA® analysis to estimate both patient risk and benefit of treatment to patients diagnosed with glioblastoma. Unlike traditional IHC, the AQUA® system is objective and produces quantitative in situ protein expression data on a continuous scale. Taking advantage of the power of the AQUA system, the present method provides a highly robust and standardized diagnostic assays that can be used in the clinical setting to provide physicians with reliable prognostic and predictive information. Glioblastoma multiform (GBM) remains one of the most aggressive human cancers, and biomarkers that provide prognostic and predictive information would be extremely valuable to both the physician and the patient. A patient's risk may be determined using the prognostic biomarkers of the present method. Such a prognostic determination will allow physicians to identify patients with a relatively ‘good’ or a relatively ‘poor’ prognosis. The benefit of treating specific patients with a specific therapy, may be determined usin̂ the predictive markers of the present method. Treatment with the AGC-family kinase inhibitor enzastaurin, for example, identifies patients that will likely benefit from treatment or not.10-25-2012
20110212465ARMET AS A MARKER FOR CANCER - Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.09-01-2011
20100203555Wild-Type Receptor Assays - A method for determining ligand activation of receptors using cells expressing genetic constructs of a fusion protein of at least a binding domain of an auxiliary protein and a fragment of β-galactosidase, a fusion protein of an endosome-associated protein and a complementary fragment of β-galactosidase, and a wild-type receptor. The receptors are characterized by binding to the auxiliary protein-binding domain upon activation by an agonist and then endocytosing associated with an endosome to which the endosome-associated protein binds. Cells are incubated with a candidate ligand followed by lysis with a lysing medium comprising a substrate for the β-galactosidase. The enzyme product is then detected as a measure of the activation of the receptor.08-12-2010
20100203554GENERIC KINASE/PHOSPHATASE ASSAY WITH SINGLE READOUT - The present invention relates to a generic method for detecting a kinase or phosphatase activity. The method comprises the following steps: incubating a kinase or phosphatase activity sample with a kinase or phosphatase substrate molecule comprising either a fluorophore having a detectable readout or molecule with an aromatic group which serves as a quencher of the fluorophore, incubating the mixture of step a) with a detection entity comprising either a fluorophore or a molecule with an aromatic group and a binding partner, wherein the substrate molecule and the detection entity are capable of binding to the binding partner and the binding of the substrate molecule and the detection entity to the binding partner lead to an altered readout of the fluorophore, and measuring the readout of the fluorophore in the mixture of step b), wherein an altered readout of the fluorophore compared to a blank is indicative for the presence of a kinase or phosphatase activity in the sample.08-12-2010
20100203553Histochemical and biomarker for liver fibrosis - The histochemical and biomarker for liver fibrosis is a technique for determining the existence and extent of liver fibrosis by evaluating the extent of peptidylarginine deiminase (PAD) activity by immunological methods. The method is illustrated using liver biopsy. A small section of tissue from a liver biopsy is incubated overnight with a monoclonal antibody specific to PAD, stained, and examined microscopically. The number of hepatocytes that positively express PAD activity per one hundred hepatocytes is counted and expressed as a percentage. The percentage of PAD activity is then correlated with a METAVIR fibrosis score according to results from a statistically significant reference population. The degree of liver fibrosis and an appropriate treatment regimen may then be determined.08-12-2010
20110236908TOTAL PLASMA FVII/FVIIA LEVELS AS INDICATORS OF PRE-ECLAMPSIA OF PREGNANT FEMALES - Raised total plasma FVII protein, including activated FVII (FVIIa) in pregnant females, compared with total plasma FVII protein in normal pregnancy, has been found to be an indicator of the pregnancy complication of pre-eclampsia.09-29-2011
20100233729DETECTING INTERACTIONS AT BIOMIMETIC INTERFACES WITH LIQUID CRYSTALS - A method of forming a liquid crystal device, includes: contacting an aqueous solution comprising a surfactant and a receptor molecule with a top surface of a liquid crystal. The liquid crystal is in a holding compartment of a substrate, and the receptor molecule is adsorbed on the top surface of the liquid crystal forming an interface between the liquid crystal and the aqueous solution. The receptor molecule is different than the surfactant. A method of detecting a compound in a flowing stream includes passing an aqueous solution over a top surface of a liquid crystal in a holding compartment of a substrate. The method also includes determining whether a change in the orientation of the liquid crystal occurs as the aqueous solution is passed over the top surface of the liquid crystal. A change in the orientation of the liquid crystal indicates the presence of the compound in the flowing stream.09-16-2010
20110294141METHOD FOR ANALYZING PSA AND METHOD FOR DISTINGUISHING PROSTATE CANCER FROM PROSTATIC HYPERTROPHY USING THAT METHOD FOR ANALYZING PSA - A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided.12-01-2011
20100216160METHOD FOR THE SCREENING PROTEASOME OF ACTIVITY-MODULATING AGENTS AND MEANS FOR CARRYIING OUT SAID METHOD - An in cellulo method for the screening of proteasome activity-modulating agents, includes the following steps of: 08-26-2010
20120329071PROTEIN BIOMARKERS AND THERAPEUTIC TARGETS FOR RENAL DISORDERS - The present invention relates to a method of diagnosing a renal disorder. The method includes the steps of: (1) obtaining a biological sample from a subject; and (2) determining, in the biological sample, a level of one or more proteins whose abundance in urine change due to the renal disorder, wherein an increase or decrease in the level of one or more of the proteins compared to a control level is indicative of a renal disorder.12-27-2012
20120329070BIOMARKER PANELS FOR ASSESSING RADIATION INJURY AND EXPOSURE - Methods and kits are provided for assessing radiation injury and exposure in a subject. The methods comprise measuring the levels of at least two (2) protein biomarkers from different biological pathways and correlating the levels with an assessment of radiation injury and exposure. Additional use of peripheral blood cell counts and serum enzyme biomarkers, evaluated in the early time frame after a suspected radiation exposure, and use of integrated multiple parameter triage tools to enhance radiation exposure discrimination and assessment are also provided. The information obtained from such methods can be used by a clinician to accurately assess the extent of radiation injury/exposure in the subject, and thus will provide a valuable tool for determining treatment protocols on a subject by subject basis.12-27-2012
20120288874ENZYMATIC ACTIVITY-BASED DETECTION - Disclosed herein are methods and kits which are useful for detecting presence of an enzyme in a test sample based upon the intrinsic enzymatic activity of such test sample. The present invention provides the ability to evaluate cell culture conditions and optimize the desired glycoform content of recombinantly prepared enzymes.11-15-2012
20100167311Oxidoreductases and Processes Utilising Such Enzymes - In Cu-containing nitrite reductase from 07-01-2010
20100167312METHOD FOR ASSAYING A TARGET ANALYTE WHILE REDUCING INTERFERENCE IN AN IMMUNOSENSOR SYSTEM - An electrochemical immunosensor system with reduced interference, comprising: a first immunosensor that generates an electrochemical signal based on the formation of a sandwich between an immobilized antibody, a target analyte and a labeled antibody, wherein a portion of the signal arises from non-specific binding of the labeled antibody in the region of the first immunosensor, and 07-01-2010
20130011857COMPLEMENT FACTOR H FOR OXIDATIVE STRESS DISEASE CONDITIONS - The invention relates to complement Factor H for use in the prevention and treatment of oxidative stress disease conditions in a patient, the use of Factor H in the preparation of a pharmaceutical preparation, and methods of determining the specific binding of Factor H to MDA and/or MAA in a sample.01-10-2013
20100129832DETECTION METHOD AND DETECTION REAGENT FOR AUTOIMMUNE PANCREATITIS OR FULMINANT TYPE-1 DIABETES - By detecting an antibody which immunologically reacts with amylase α2-A in a sample, AIP or FT1DM is examined or the possibility of developing FT1DM is determined. Detection of this antibody is for instance carried out by an immunological method using an antigen which immunologically reacts with this antibody. The antigen is preferably a partial fragment containing the amino acid sequence of amino acid numbers 299 to 512 of human amylase α2-A.05-27-2010
20130017557COMBINATION OF sPLA2 TYPE IIA MASS AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENTAANM Mallat; ZiadAACI ParisAACO FRAAGP Mallat; Ziad Paris FRAANM Tedgui; AlainAACI ParisAACO FRAAGP Tedgui; Alain Paris FRAANM Tsimikas; SotiriosAACI La JollaAAST CAAACO USAAGP Tsimikas; Sotirios La Jolla CA USAANM Witztum; JosephAACI La JollaAAST CAAACO USAAGP Witztum; Joseph La Jolla CA US - The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), —combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.01-17-2013
20130017556ASSAYS FOR HDL BIOMOLECULAR INTERACTIONS - The invention relates to methods, compositions and kits for detecting molecular interactions. In one embodiment, the invention relates to methods for quantifying HDL interactions with biomolecules. In still another embodiment, the invention relates to methods for determining HDL function.01-17-2013
20130017558ADAM12 AS A BIOMARKER FOR BLADDER CANCER - The invention generally relates to isolated human or humanized antibodies or functional fragments thereof that include an antigen binding region that specifically binds a form of a disintegrin and metalloprotease 12 (ADAM12) present in a tissue or body fluid that is indicative of a cancer.01-17-2013
20110159521METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The invention provides an ELISA assay for the determination of serum mast cell β-tryptase levels using rabbit anti-tryptase as the capture antibody and alkaline phosphatase conjugated G3 as the detecting antibody. Luminescent substrate CPSD was used to enhance the assay sensitivity. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of β-tryptase, histamine and/or prostaglandin E06-30-2011
20080254485Methods And Compositions For Monitoring And Risk Prediction In Cardiorenal Syndrome - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.10-16-2008
20080227116Histaminase Determination - Disclosed is a method for determining histaminase (DAO; EC 1.4.3.6) activity in a sample. Said method comprises the following steps: an aqueous solution is supplied which contains a predefined amount of a diamine; the aqueous solution is mixed and incubated with the sample for a given period of time in conditions in which the diamine can be reacted with a DAO possibly present in the sample; the diamine is derivatized; the amount of derivatized diamine is determined; the predefined amount of diamine is compared to the amount of derivatized diamine; and the activity of histaminase possibly present is determined.09-18-2008
20130177924LINKED PEPTIDE FLUOROGENIC BIOSENSORS - Biosensors, compositions comprising biosensors, methods of producing biosensors, and methods of using biosensors are disclosed. The biosensors comprise a fluorogen-activating peptide and a blocking peptide. The fluorogen-activating peptide and blocking peptide are covalently linked through a peptide linker. The blocking peptide associates with the fluorogen-activating peptide thereby blocking an active domain of the fluorogen-activating peptide when the linker is in an unmodified state. The peptide linker may contain an amino acid sequence that is specifically recognized as a modification substrate by a cognate enzyme. The fluorogen-activating peptide and the blocking peptide at least partially disassociate when the linker is modified by an enzyme, thereby allowing the fluorogen-activating peptide to bind a cognate fluorogen and modulate a fluorescence signal.07-11-2013
20130171659METHODS OF PROGNOSIS AND DIAGNOSIS OF RHEUMATOID ARTHRITIS - Provided are methods of diagnosing rheumatoid arthritis in a patient by detecting the presence and/or amount of a biomarker of rheumatoid arthritis in a sample from the patient. The methods and biomarkers may be used to develop an accurate prognosis for a patient having rheumatoid arthritis or suspected of having rheumatoid arthritis, or to accurately diagnose a patient having, or suspected of having rheumatoid arthritis. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for a rheumatoid arthritis therapy.07-04-2013
20130171660BLOOD MARKER FOR RENAL CANCER - The present invention provides a blood marker for renal cancer, more specifically, a blood marker that can be practically used for clinical diagnosis of renal cancer. The present invention also provides a blood marker that can be practically used for follow-up after treatment such as surgery and during treatment such as medication for renal cancer. A blood marker for renal cancer selected from the group consisting of Galectin-1, Galectin-3, and α-enolase. Galectin-1 and/or Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging. α-Enolase as a blood marker for renal cancer for use in monitoring during and/or after treatment for renal cancer.07-04-2013
20130171661Assay for Identification of LRRK2 Inhibitors - A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method may comprise or further comprise the step of assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the subcellular location of LRRK2. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems.07-04-2013
20130137116METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance of NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.05-30-2013
20110269150Compositions and methods for predicting cardiovascular events - The present invention provides compositions, devices, kits, and methods for determining the risk of peri-operative cardiovascular events or predicting cardiovascular events associated with angioplasty. In certain embodiments, the present invention provides methods, compositions, kits, and devices configured for determining the value of at least two markers selected from myeloperoxidase (MPO), an F2-isoprostane (F2-IsoP), C-reactive protein (CRP), urinary micro-albumin (UMA), and lipoprotein-associated phospholipase A2 (Lp-PLAZ), such that a subject's risk of experiencing a cardiovascular event is determined.11-03-2011
20130177923DIAGNOSTIC USE OF INDIVIDUAL MOLECULAR FORMS OF A BIOMARKER - Methods are provided of diagnosing, monitoring or determining the severity of disease or injury by measuring individual molecular forms of neutrophil gelatinase-associated lipocalin (NGAL) in bodily fluids, including the diagnosis and monitoring of acute renal injury leading to acute renal failure in a human or mammalian subject by determining the concentration of the free monomer form of NGAL.07-11-2013
20130095504DISEASE MARKER DETECTION KIT AND DISEASE MARKER DETECTION METHOD - Provided is a detection kit, which a disease detection kit used together with a secondary ion mass spectrometer in order to detect a disease marker contained in a biological sample, the detection kit including: a base including a noble metal thin film formed thereon; a reactant containing peptide specifically reacting with the disease marker; a first storage unit filled with the reactant; a test substance containing a biological sample of a possible disease carrier; a second storage unit filled with the test substance; a mixing unit mixing the reactant and the test substance with each other to prepare a detection substance containing the specific reactant, which is the peptide specifically reacted with the disease marker contained in the biological sample; and a contact unit contacting the detection substance prepared by the mixing unit with the base to bond the specific reactant to the noble metal film of the base.04-18-2013
20130102009SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS - Provided are methods and compositions for detecting a compound that activates a sirtuin deacetylase activity on a fluorescent-free activation substrate in vitro. Further provided are sirtuin modulating compounds of the formulas (I)-(XXI), and related compounds (XXXI), (XXXII), (XXXIII), and (XXXIV), including the fluorescent free-substrate SIRT1 activator compounds of formulas (XL), (XI), (XII), and (XIII).04-25-2013
20130130277REMEDY FOR DIABETES - A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the β subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the β subunit of a trimeric GTP-binding protein, as the active ingredient, etc.05-23-2013
20130143232METHODS FOR THE DETECTION AND MONITORING OF ACUTE MYOCARDIAL INFARCTION - Disclosed herein are methods of detecting and/or prognosing myocardial infarction by detecting a proteolytic fragment of caspase-3 such as the p17 fragment or the p12 fragment. The myocardial infarction can be STEMI or NSTEMI.06-06-2013
20130203073ASSAY FOR ANALYTES BASED ON AGGREGATION - The present invention relates to compositions, assay devices, kits and methods for detecting the presence, amount and/or activity of an analyte in a sample. In particular, the present invention relates to the detection of enzymes. The present invention also relates to methods of diagnosing diseases associated with dysregulation of enzymes, screening for modulators of enzymatic activity, candidate antimicrobial peptides and toxins.08-08-2013
20130149713BIOMARKERS OF HEMORRHAGIC SHOCK - Methods for the use of keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) (KC/GRO), apolipoprotein A2 (APOA2), angiotensinogen r (AGT), thyroglobulin (TG), disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), anionic trypsin-1 (PRSS1), complement C4 (C4A), zona pellucida sperm-binding protein 1 (ZP1), neuropilin-2 (NRP2), solute carrier family 13 member 2 (SLC13A2), glucagon-like peptide 2 receptor (GLP2R), lipoma high mobility group protein isoform I-C (HMGIC) fusion partner-like protein 4 (LHFPL4), and claudin-3 (CLDN3) as biomarkers for diagnosis and prognosis, and for monitoring the efficacy of treatment, in hemorrhagic shock (HS).06-13-2013
20130149714BIO-DIAGNOSTIC TESTING SYSTEM AND METHODS - An implantable diagnostic device in accordance with the present disclosure includes a probe assembly that can be implemented in a variety of ways. A few example implementations include: a needle inside which is located a bio-sensor chip (the needle being insertable into a human being); a compact package containing the bio-sensor chip (the compact package configured for placement inside a catheter); or a silicon-based bio-sensor package configured for insertion into a vein.06-13-2013
20120276551METHODS PREDICTING RISK OF AN ADVERSE CLINICAL OUTCOME - Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation 5 in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 and a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the in the methods described.11-01-2012
20120258468INDICATOR AGENT FOR NONINFLAMMATORY STRESS RESPONSE AND USE THEREOF - A system enabling the molecular biological visualization and quantitative detection of events in a stress-exposed living organism and a means enabling the management of stress are provided. An indicator agent for non-inflammatory stress responses mediated by superoxide, which comprises IL-18, a visualizing agent for non-inflammatory stress responses for detecting the aforementioned indicator agent, a method of measuring the degree of non-inflammatory stress, which comprises using the aforementioned visualizing agent, a method of preventing, ameliorating or predicting a change in immune status based on a non-inflammatory stress response, which comprises applying the aforementioned visualizing agent to an animal, and a therapeutic agent for a change in immune status based on a non-inflammatory stress response for reducing the amount or activity of the aforementioned indicator agent.10-11-2012
20100304404MOLECULAR MODIFICATION ASSAYS - Systems for detecting molecular modifications and the presence and/or activity of enzymes and/or other agents involved in facilitating or otherwise regulating such modifications.12-02-2010
20100317031ULTRA-SENSITIVE CHEMILUMINESCENT SUBSTRATES FOR ENZYMES AND THEIR CONJUGATES - New chemiluminescent compounds, stable in aqueous buffers, for use in biological assaying include acridane-based compounds and 1,2-dioxetanes. Among the new acridane-based compounds are water-soluble acridanes, enhancer coupled acridanes, bis and tris-acridanes as well as acridane-1,2-dioxetanes. Among the new 1,2-dioxetanes are electron deficient group-containing dioxetanes and tethered bis-1,2-dioxetanes. The 1,2-dioxetanes are useful as substrates for various enzymes. The acridanes can be admixed with an oxidizing agent an aqueous buffer and, optionally, a stabilizer to form a substrate or reagent formulation useful for assaying, inter alia, HRP.12-16-2010
20100317029Nasopharyngeal cancer malingancy biomarker and method thereof - The present invention discloses a nasopharyngeal cancer malignancy biomarker and a method thereof, wherein relative TP expression is used to evaluate the malignancy of nasopharyngeal cancer. The biomarker of the present invention assists the currently-existing inspections to find out cancer in the early stage and achieve early diagnosis and early therapy. The present invention also functions as an effective indicator to monitor the metastasis and relapse of nasopharyngeal cancer.12-16-2010
20130157288IMMOBILISED-BEAD IMMUNOMULTIPLEX ASSAY - Embodiments of this invention include image-based systems and methods for detection of one or more analytes. A surface has identifiable analyte-specific capture particle(s) immobilised thereto at any point of an assay, to which different analytes attach due to the affinity of analyte-specific capture molecule(s) linked to the surface of the capture particle(s) for the analyte. Analyte-specific detector molecules with conjugated detection moieties are then attached to the analyte, and a computer assisted, image-based detection system captures images of the capture particles with or without attached analytes and detector molecules. By using different subsets of analyte-specific capture molecules, each subset having a characteristic identifiable feature; it is now possible to perform capture particle-based, rapid multiplex assays of biological and non-biological analytes without flow. These image-based systems can be used to aid in diagnosis of disease, evaluation of therapy for disease, or laboratory investigation.06-20-2013
20120282627CRYSTAL OF HYPOXIA INDUCIBLE FACTOR 1 ALPHA PROLYL HYDROXYLASE - The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.11-08-2012
20130183685METHOD OF RECOMBINANT MACROMOLECULAR PRODUCTION - A method for recombinantly expressing a macromolecule in a host cell is disclosed which involves culturing a host cell which contains two nucleic acid sequences, i.e., a first nucleic acid sequence encoding a membrane-permeabilizing agent and a second nucleic acid sequence encoding a desired macromolecule under the operative control of an inducible promoter, to a selected cell density that permits accumulation of the agent. Thereafter the host cell is exposed to an environmental condition that induces the agent to disrupt the integrity of the cell membrane without complete lysis of the cell membrane. The host cell thereby allows transport through the membrane of small molecular weight compounds. These resulting host cells are cultured in the presence of a nutrient cocktail that contains components that can transport through the disrupted cell membrane, e.g., an inducing agent that induces the tightly regulated promoter and metabolic requirements that permit expression of the macromolecule.07-18-2013
20130183684PROTEIN BIOMARKERS FOR OBSTRUCTIVE AIRWAYS DISEASES - Provided herein are methods for the diagnosis of obstructive airways diseases such as asthma and chronic obstructive pulmonary disease, and the discrimination between such diseases based on the expression profiles of biomarker proteins and combinations of biomarker proteins. In particular embodiments the biomarker proteins are selected from ceruloplasmin, haptoglobin, hemopexin, -07-18-2013
20130183683METHODS OF DIAGNOSING ACUTE CARDIAC DISORDERS USING BNP-SP - The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.07-18-2013
20110306058METHOD FOR THE FUNCTIONAL MEASUREMENT OF PLASMATIC THROMBODULINE ACTIVITY - A method for the in vitro measurement of the thromboduline functional activity, includes dosing in a biological medium, and from a biological sample, the thrombine-activation of C protein into activated C protein (PCa) in the presence of its co-factor or the thromboduline, the method including adding to the sample plasma the agents necessary for activating the C protein system, adding purified C protein and also adding a fibrin polymerisation inhibitor. Also described is application of the method in the detection of coagulation pathologies.12-15-2011
20130189706BIOSENSOR USING WHISPERING GALLERY MODES IN MICROSPHERES - A biosensor for detecting the presence of a target analyte is disclosed. The biosensor is formed from microspheroidal particles which have had a binding partner for the target analyte immobilized on their surfaces. The binding partners may be nucleotides; peptides, proteins, enzymes, antibodies and so on. When the analyte binds to its partner, the whispering gallery mode (WGM) profiles of the micro spheroidal particles change such that the profile peaks undergo a red- or blue-shift. The immobilized binding partners may include fluorophores and the like so that they emit fluorescence, phosphorescence, incandescence and the like. These fluorophores may take the form of a nanocrystal or quantum dot.07-25-2013
20120028274PROTEIN KINASE C GAMMA AS A BIOMARKER FOR NEUROPSYCHOLOGICAL AND COGNITIVE FUNCTIONS IN THE CENTRAL NERVOUS SYSTEM - Embodiments of the present invention are directed to a biological marker, the gamma isoform of protein kinase C (PKCg), which surprisingly allows rapid identification of compromised cognitive, behavioral, and neuropsychological functions under conditions associated with acute, transient hypoxia in humans. It was surprisingly discovered that PKCg is released from neural cells and can be detected in peripheral blood after hypoxic events unrelated to the reduction or elimination of blood flow through affected tissues. Embodiments of this invention are also directed to a broad range of clinical applications, particularly in emergency medicine. Other embodiments are related to compositions and methods for distinguishing between hypoxic encephalopathies and conditions arising from neuroanatomical/structural anomalies and/or incidental pathologies, for example, alcohol intoxication.02-02-2012
20130196343SIGNAL LOCKING LABEL FREE BIOSENSING - A biosensor can include a fluid flow channel (08-01-2013
20130196342Compositions And Methods For Modulating S-Nitrosogluthione Reductase - Disclosed herein are methods and compositions for modulating the levels and/or activity of S-nitrosoglutathione reductase (GSNOR) in vivo or in vitro. Specifically disclosed are GSNOR deletion constructs, host cells and non-human mammals comprising GSNOR deletions, and methods of screening employing GSNOR deletion mutants. Also specifically disclosed are reagents and procedures for measuring, monitoring, or altering GSNOR levels or activity (as well as nitric oxide and S-nitrosothiol levels) in connection with various medical conditions.08-01-2013
20130203074METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 as diagnostic and prognostic biomarkers in renal injuries.08-08-2013
20120077208USE OF CARBAMOYL PHOSPHATE SYNTHETASE 1 (CPS) AS A HUMORAL BIOMARKER FOR THE DIAGNOSIS OF TUMOUR DISEASES AND CHRONIC INFLAMMATORY INTESTINAL DISEASES - The invention relates to the use of carbamoyl synthetase 1 (CPS 1) as a humoral biomarker in in vitro methods for early diagnosis and detection, progress prognosis, the evaluation of the severity, and the progress evaluation of tumor diseases and chronic inflammatory intestinal diseases.03-29-2012
20130095502REAGENTS AND METHODS FOR PHOSPHORYLATION/DEPHOSPHORYLATION ANALYSES - Disclosed herein are reagents that include a moiety that includes a metal such as titanium and that readily binds to phosphorylated molecules the reagents also include at least one moiety that produces a signal or that binds to a molecule that produces a signal. The reagent may also include a moiety that binds to a larger molecule or to a surface. Some forms of the reagent include a dendrimer that can simultaneously bind to multiple metal moieties that include a metal such as titanium and multiple moieties that can be used to detected bound molecules. These reagents can be used in detection and/or measurement and/or at least partial purification of phosphorylated molecules. These reagents and methods using them are used to analyze proteins, polypeptides, nucleic acids, phospholipids and the like. They are readily adapted for use in gels, blots, plate based high through put assays and for mass spectrometry.04-18-2013
20130095503SERUM SPLA2-IIA AS DIAGNOSIS MARKER FOR PROSTATE AND LUNG CANCER - Kits for assessing lung cancer in patients with solitary pulmonary nodules and methods for assessing lung cancer. The kit includes reagents for detection and/or quantification of serum secretory phospholipase A04-18-2013
20120094307TUBE FOR MEASURING BIO-RELATED SUBSTANCE AND QUANTIFYING SYSTEM - A bio-related substance assay tube 04-19-2012
20130210029METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN A NON-SURGICAL ICU POPULATION - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects admitted to a hospital critical care setting for other than a post-surgical or trauma indication. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Insulin-like growth factor IA, soluble Epidermal growth factor receptor, and Leukocyte elastase as diagnostic and prognostic biomarkers in renal injuries.08-15-2013
20130210030IN VIVO METHOD FOR THE EVALUATION OF A COMPOUND-TARGET INTERACTION - The invention relates to a method for evaluation of a compound-target interaction in vivo, comprising the steps of administering the compound to an animal, taking a body fluid sample of the animal, determining the concentration of the compound in the body fluid sample, taking a cellular sample of the animal containing the target, preparing a protein preparation of said cellular sample, providing an immobilised ligand capable of binding to the target, contacting the protein preparation with the immobilised ligand under conditions allowing the formation of a complex between the immobilised ligand and the target, determining the amount of complexes formed in step, and correlating the amount of complexes with the concentration of the compound in the body fluid sample.08-15-2013
20130210031DETECTION OF ADENYLATE CYCLASE - One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result, are rendered unusable after antibiotic use, or are not quantifiable. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, by the time a diagnosis is made a patient may be days beyond the time when treatment would be effective. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax edema factor activity exhibited by the invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines, anti-toxins and edema factor inhibitors. The invention isolates and concentrates edema factor and edema toxin from nearly any sample. By capitalizing on the adenylate cyclase activity of edema factor the invention amplifies output signals producing reliable detection of low concentrations of edema factor previously unachievable. The invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax edema factor, and other adenylate cyclases in biological samples.08-15-2013
20090263866Industrial-scale Serum-free Production of Recombinant Factor VII in Mammalian Cells - The invention provides a method for industrial-scale production of FVII polypeptides in mammalian cell culture free of animal-derived components.10-22-2009
20110171689ARTIFICIAL IMMUNE SYSTEM: METHODS FOR MAKING AND USE - The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.07-14-2011

Patent applications in class To identify an enzyme or isoenzyme